Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug, a central nervous system stimulant, a xenobiotic and an environmental contaminant. It is a member of amphetamines and a secondary amine. It is functionally related to a (S)-amphetamine. It is a conjugate base of a methamphetamine(1+).

Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.

Methamphetamine is an Amphetamine Anorectic and Central Nervous System Stimulant. The physiologic effect of methamphetamine is by means of Appetite Suppression and Central Nervous System Stimulation and Increased Sympathetic Activity.

Methamphetamine has been reported in Senegalia berlandieri and Vachellia rigidula with data available.

Methamphetamine is an amphetamine with central nervous system (CNS) stimulating activity. Methamphetamine acts by both facilitating the release of catecholamines, particularly noradrenaline, dopamine and serotonin, from nerve terminals in the brain and by inhibiting their uptake. This leads to an increase in synaptic concentration of these neurotransmitters and results in increased stimulation of postsynaptic receptors.

METHAMPHETAMINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1943 and is indicated for attention deficit hyperactivity disorder and has 2 investigational indications. This drug has a black box warning from the FDA. Breast Feeding; Lactation; Milk, Human; Street Drugs; Sympathomimetics; Dopamine Agents; Central Nervous System Stimulants; Adrenergic Agents; Wakefulness-Promoting Agents

Methamphetamine is a psychostimulant and sympathomimetic drug. It is a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse.

A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.

Mechanism of Action

Methamphetamine enters the brain and triggers a cascading release of norepinephrine, dopamine and serotonin. To a lesser extent methamphetamine acts as a dopaminergic and adrenergic reuptake inhibitor and in high concentrations as a monamine oxidase inhibitor (MAOI). The mechanism of action involved in producing the beneficial behavioral changes seen in hyperkinetic children receiving methamphetamine is unknown. Appears to exert most or all of its effect in the CNS by causing release of biogenic amines, especialy norepinephrine and dopamine, from storage sites in nerve terminals. It may also slow down catecholamine metabolism by inhibiting monoamine oxidase. The toxic effects of methamphetamine on dopamine and serotonergic neurons have recently been linked to the endogenous formation of c-hydroxy dopamine and 5, 7 dihydrotryptamine, respectively. The ability of methamphetamine to both release dopamine and serotonin as well as to inhibit monoamine oxidase activity leads to the non-enzymatic oxidation of dopamine and serotonin. Methamphetamine induced neuronal damage is mediated by the production of free radicals. This drug causes a long lasting depletion of dopamine and serotonin in the striatum and that pre-treatment alteration of this effect by four different antioxidants, as well as an inhibitor of superoxidase dismutase, indicate that oxygen free radicals have a role in methamphetamine induced neurotoxicity.

Methamphetamine is a potent central nervous system stimulant which affects neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and responses associated with alertness or alarm conditions. The acute effects of the drug closely resemble the physiological and psychological effects of an epinephrine-provoked fight-or-flight response, including increased heart rate and blood pressure, vasoconstriction (constriction of the arterial walls), bronchodilation, and hyperglycemia (increased blood sugar). Users experience an increase in focus, increased mental alertness, and the elimination of fatigue, as well as a decrease in appetite.

Drug Indications

For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.

Sympathomimetics; Dopamine Agents; Central Nervous System Stimulants; Adrenergic Agents; Wakefulness-Promoting Agents

Adrenergic Agents; Adrenergic Uptake Inhibitors; Appetite Depressants; Central Nervous System Stimulants; Dopamine Agents; Dopamine Uptake Inhibitors; Sympathomimetics.

Methamphetamine also is used as an adjunct to psychological, educational, social, and other remedial measures in the treatment of attention deficit hyperactivity disorder (ADHD).
Methamphetamine has been used as an adjunct to caloric restriction in the short-term (i.e., a few weeks) treatment of exogenous obesity. However, short-term or intermittent therapy with methamphetamine is unlikely to maintain a long-term benefit, and prolonged administration of methamphetamine for the treatment of obesity is not indicated.
To stimulate central & sympathetic nervous systems to overcome depression, incr blood pressure by vasoconstriction, & as antidote to barbiturate overdosage. Resp stimulant. Reliability as post-anesthetic analeptic has been questioned.

As an integral part of a total treatment program for attention deficit disorder with hyperactivity, which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in patients with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity

Contraindications

Known hypersensitivity to amphetamine, or any of the ingredients in this product
With monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs (including MAOIs such as linezolid or IV methylene blue) due to an increased risk of hypertensive crisis.

Having thoughts of suicide
Tourette syndrome
Hyperthyroidism

Bipolar disorder
Psychotic disorder
Drug abuse

Behaving with excessive cheerfulness or activity
Chronic muscle twitches or movements
Aggressive behavior

Increased ophthalmic pressure
Hypertension
History of a heart attack

Coronary artery disease
Cardiomyopathy
Arrhythmia

Chronic heart failure
Stroke
Atherosclerosis

Numbness
Prickling
Tingling of fingers and toes

Seizures
Loss of appetite
Weight loss

Breastfeeding mothers
Increased cardiovascular event risk
Structural disorder of the heart

Chronic kidney disease stage 4 (severe) or 5 (failure)
Kidney disease with a likely reduction in kidney function
Allergic reaction to sympathomimetic agents or amphetamine analogs

Dosage

Strengths: 5 mg; 10 mg; 15 mg

Pediatric Dose for Attention Deficit Disorder

6 years and older:

Initial dose: 5 mg orally once or twice a day

Titration dose: May increase daily dosage by 5 mg at weekly intervals until achieving optimum clinical response
Maintenance dose: The usual effective dose is 20 to 25 mg per day.
The total daily dose may be given in 2 divided doses.

Administration advice:

Before therapy, assess for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam).
Before therapy, assess the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome.
Administer this drug at the lowest effective dosage; individually adjust dosage.

Avoid late evening medication due to the resulting insomnia.

General:

The diagnosis of attention deficit disorder with hyperactivity should not be made with finality when the symptoms (moderate to severe distractibility, short attention span, hyperactivity, emotional lability, impulsivity) are only of comparatively recent origin.
Nonlocalizing (soft) neurological signs, learning disability, and abnormal electroencephalogram may or may not be present, and a diagnosis of CNS dysfunction may or may not be warranted.

Hypersensitivity reactions (e.g., angioedema, anaphylactic reactions) have been reported in patients treated with other amphetamine products.
Prescribing and dispensing of this drug should be limited to the smallest amount feasible at one time to minimize the possibility of overdosage.

Side Effects

People who use methamphetamine feel an acute, powerful short rush for about 5 to 30 minutes, which varies based on different routes of use. The drug also causes an enhanced energy level, decreases appetite, and creates euphoria for a range of 6 to 12 hours.

The Most Common

Decreased appetite
Nausea
Psychosis

Tachycardia
Hypertension
Increased body temperature

Panic attack
Mydriasis (dilation of pupils)
Disturbed sleep patterns

Violent, bizarre, and erratic behavior
Hallucinations and irritability
Seizures, convulsions, and death from high doses

Long-lasting damage to the blood vessel of the heart and brain
Lung, liver, and kidney damage
Hypertension that can lead to heart attacks, strokes, and death

Severe tooth degeneration
In cases where the drug was sniffed, destruction of soft tissues in the nose
In cases where the drug was smoked, respiratory problems

In cases where the drug was injected, infectious diseases, cellulitis, and abscesses
Weight loss and malnutrition
Disorientation, apathy, confusion, and exhaustion

Severe psychological dependence
Psychosis
Depression

Damage to the brain structure similar to Alzheimer disease, epilepsy, and stroke

More Common

aggressive
agitation

angry
blurred vision
change in consciousness

chest pain or discomfort
confusion
dark urine

diarrhea
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
fainting

fast breathing
fast, slow, or irregular heartbeat
fever

headache
inability to speak
loss of consciousness

muscle cramps, spasms, pain, or stiffness
nausea
nervousness

overactive reflexes
pain or discomfort in the arms, jaw, back, or neck
pale, clammy skin

palpitations
pounding in the ears
restlessness

seeing, hearing, or feeling things that are not there
seizures
shivering

slow or fast heartbeat
slurred speech
stomach cramps

sweating
talking or acting with excitement you cannot control
temporary blindness

thirst
tremor
trouble breathing

unusual tiredness or weakness
vomiting
weakness in the arm or leg on one side of the body, sudden and severe

Rare

bad, unusual, or unpleasant (after) taste
change in taste
constipation

decreased interest in sexual intercourse
dry mouth
hives or welts, itching, or skin rash

inability to have or keep an erection
indigestion
loss in sexual ability, desire, drive, or performance

passing of gas
redness of the skin
weight loss

The last stage of methamphetamine misuse happens when the person who inappropriately uses methamphetamine becomes paranoid and irritable because of a lack of sleep for about 3 to 15 days. This behavior is called “tweaking,” and the person with this behavior is known as the “tweaker.” Usually, tweakers continue to require more methamphetamine to get to the original high. This effect is difficult to achieve, which causes frustration and irritability, and unsteady behavior in the tweaker. Because tweakers are unpredictable, they can behave violently, can get involved in domestic arguments, spur-of-the-moment offenses, and become a danger to others or themselves. A tweaker can behave normally and have clear eyes, concise speech, and brisk movements; however, careful observation will indicate that the person’s eye movement is much faster than normal (up to 10 times). They have a minor quiver voice and jerky movements. Some tweakers minimize or cover these physical symptoms by using a depressant like alcohol or opioids; however, the use of a depressant by the tweaker increases his or her negative feelings of paranoia, irritability, and frustration significantly. Other people around these users should use extreme caution because of their unpredictable behaviors.

Drug Interactions

Drug	Interaction
Abacavir	Abacavir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Abatacept	The metabolism of Metamfetamine can be increased when combined with Abatacept.
Abiraterone	The metabolism of Metamfetamine can be decreased when combined with Abiraterone.
Acebutolol	The therapeutic efficacy of Acebutolol can be decreased when used in combination with Metamfetamine.
Aceclofenac	The risk or severity of hypertension can be increased when Metamfetamine is combined with Aceclofenac.
Acemetacin	The risk or severity of hypertension can be increased when Metamfetamine is combined with Acemetacin.
Acetaminophen	Acetaminophen may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Acetazolamide	Acetazolamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Acetophenazine	Acetophenazine may decrease the stimulatory activities of Metamfetamine.
Acetylsalicylic acid	The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Metamfetamine.
Aclidinium	Metamfetamine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Metamfetamine may decrease the sedative activities of Acrivastine.
Acyclovir	Acyclovir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Adagrasib	The metabolism of Metamfetamine can be decreased when combined with Adagrasib.
Adalimumab	The metabolism of Metamfetamine can be increased when combined with Adalimumab.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Adenosine	The risk or severity of Tachycardia can be increased when Adenosine is combined with Metamfetamine.
Adrafinil	The risk or severity of hypertension can be increased when Metamfetamine is combined with Adrafinil.
Albuterol	The risk or severity of hypertension can be increased when Salbutamol is combined with Metamfetamine.
Albutrepenonacog alfa	Metamfetamine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	The risk or severity of hypertension can be increased when Metamfetamine is combined with Alclofenac.
Aldesleukin	Aldesleukin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Alfentanil	Metamfetamine may increase the analgesic activities of Alfentanil.
Alfuzosin	The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Metamfetamine.
Alimemazine	Metamfetamine may decrease the sedative activities of Alimemazine.
Aliskiren	Metamfetamine may decrease the antihypertensive activities of Aliskiren.
Allopurinol	Allopurinol may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Almasilate	The serum concentration of Metamfetamine can be increased when it is combined with Almasilate.
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Metamfetamine.
Alogliptin	Metamfetamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Alprazolam	Alprazolam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Alprenolol	The therapeutic efficacy of Alprenolol can be decreased when used in combination with Metamfetamine.
Aluminium phosphate	The serum concentration of Metamfetamine can be increased when it is combined with Aluminium phosphate.
Aluminum hydroxide	The serum concentration of Metamfetamine can be increased when it is combined with Aluminum hydroxide.
Amantadine	The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Metamfetamine.
Ambrisentan	Metamfetamine may decrease the antihypertensive activities of Ambrisentan.
Amikacin	Metamfetamine may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Amineptine	The therapeutic efficacy of Amineptine can be increased when used in combination with Metamfetamine.
Aminophenazone	The risk or severity of hypertension can be increased when Aminophenazone is combined with Metamfetamine.
Aminophylline	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Aminophylline.
Amiodarone	The metabolism of Metamfetamine can be decreased when combined with Amiodarone.
Amisulpride	Amisulpride may decrease the stimulatory activities of Metamfetamine.
Amitriptyline	Metamfetamine may decrease the sedative activities of Amitriptyline.
Amitriptylinoxide	The therapeutic efficacy of Amitriptylinoxide can be increased when used in combination with Metamfetamine.
Amlodipine	Metamfetamine may decrease the antihypertensive activities of Amlodipine.
Ammonium chloride	The serum concentration of Metamfetamine can be decreased when it is combined with Ammonium chloride.
Amoxapine	Metamfetamine may decrease the sedative activities of Amoxapine.
Amoxicillin	Amoxicillin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Amphetamine	The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Metamfetamine.
Amphotericin B	Amphotericin B may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ampicillin	Ampicillin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Amprenavir	The metabolism of Metamfetamine can be decreased when combined with Amprenavir.
Amrinone	Amrinone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Anagrelide	The risk or severity of Tachycardia can be increased when Anagrelide is combined with Metamfetamine.
Anakinra	The metabolism of Metamfetamine can be increased when combined with Anakinra.
Ancestim	Metamfetamine may decrease the excretion rate of Ancestim which could result in a higher serum level.
Anisotropine	The risk or severity of Tachycardia can be increased when Anisotropine methylbromide is combined with Metamfetamine.
Antazoline	Metamfetamine may decrease the sedative activities of Antazoline.
Antihemophilic	Metamfetamine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antipyrine	The risk or severity of hypertension can be increased when Antipyrine is combined with Metamfetamine.
Antithrombin III	Metamfetamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antrafenine	The risk or severity of hypertension can be increased when Antrafenine is combined with Metamfetamine.
Apalutamide	Metamfetamine may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Apomorphine	The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Metamfetamine.
Apremilast	The metabolism of Metamfetamine can be increased when combined with Apremilast.
Aprocitentan	Metamfetamine may decrease the antihypertensive activities of Aprocitentan.
Arbutamine	The risk or severity of hypertension can be increased when Arbutamine is combined with Metamfetamine.
Arformoterol	The risk or severity of hypertension can be increased when Arformoterol is combined with Metamfetamine.
Aripiprazole	Metamfetamine may decrease the sedative activities of Aripiprazole.
Aripiprazole lauroxil	Metamfetamine may decrease the sedative activities of Aripiprazole lauroxil.
Armodafinil	The risk or severity of hypertension can be increased when Metamfetamine is combined with Armodafinil.
Arsenic trioxide	Arsenic trioxide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Artenimol	The metabolism of Metamfetamine can be decreased when combined with Artenimol.
Ascorbic acid	The serum concentration of Metamfetamine can be decreased when it is combined with Ascorbic acid.
Asenapine	Metamfetamine may decrease the sedative activities of Asenapine.
Astemizole	Metamfetamine may decrease the sedative activities of Astemizole.
Asunaprevir	The metabolism of Metamfetamine can be decreased when combined with Asunaprevir.
Atazanavir	Atazanavir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Atenolol	The therapeutic efficacy of Atenolol can be decreased when used in combination with Metamfetamine.
Atomoxetine	The risk or severity of hypertension can be increased when Atomoxetine is combined with Metamfetamine.
Atropine	The risk or severity of hypertension can be increased when Atropine is combined with Metamfetamine.
Auranofin	Auranofin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Aurothioglucose	Metamfetamine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Azacitidine	Azacitidine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Azapropazone	The risk or severity of hypertension can be increased when Metamfetamine is combined with Azapropazone.
Azatadine	Metamfetamine may decrease the sedative activities of Azatadine.
Azathioprine	Azathioprine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Azelaic acid	Azelaic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Azelastine	Metamfetamine may decrease the sedative activities of Azelastine.
Azilsartan med	Metamfetamine may decrease the antihypertensive activities of Azilsartan medoxomil.
Aztreonam	Aztreonam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Bacitracin	Bacitracin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Baclofen	Baclofen may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Balsalazide	The risk or severity of hypertension can be increased when Balsalazide is combined with Metamfetamine.
Baricitinib	Metamfetamine may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Benactyzine	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Benactyzine.
Benazepril	Metamfetamine may decrease the antihypertensive activities of Benazepril.
Bendroflumeth	Metamfetamine may decrease the antihypertensive activities of Bendroflumethiazide.
Benmoxin	Benmoxin may increase the hypertensive activities of Metamfetamine.

Benorilate	The risk or severity of hypertension can be increased when Metamfetamine is combined with Benorilate.
Benoxaprofen	The risk or severity of hypertension can be increased when Metamfetamine is combined with Benoxaprofen.
Benperidol	Benperidol may decrease the stimulatory activities of Metamfetamine.
Benserazide	Metamfetamine may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	Metamfetamine may decrease the sedative activities of Benzatropine.
Benzhydrocodone	Metamfetamine may increase the analgesic activities of Benzhydrocodone.
Benznidazole	Metamfetamine may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The metabolism of Metamfetamine can be decreased when combined with Benzocaine.
Benzphetamine	The risk or severity of serotonin syndrome can be increased when Benzphetamine is combined with Metamfetamine.
Benzquinamide	Metamfetamine may decrease the sedative activities of Benzquinamide.
Benzthiazide	Benzthiazide may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	The risk or severity of hypertension can be increased when Metamfetamine is combined with Benzydamine.
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Metamfetamine.
Benzylpenicilloyl	Metamfetamine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Bepotastine	Metamfetamine may decrease the sedative activities of Bepotastine.
Bepridil	The metabolism of Metamfetamine can be decreased when combined with Bepridil.
Berotralstat	The metabolism of Metamfetamine can be decreased when combined with Berotralstat.
Betahistine	Metamfetamine may decrease the sedative activities of Betahistine.
Betaxolol	The therapeutic efficacy of Betaxolol can be decreased when used in combination with Metamfetamine.
Bethanidine	Metamfetamine may decrease the antihypertensive activities of Bethanidine.
Bezitramide	Metamfetamine may increase the analgesic activities of Bezitramide.
Bicisate	Metamfetamine may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bilastine	Metamfetamine may decrease the sedative activities of Bilastine.
Bimekizumab	The metabolism of Metamfetamine can be increased when combined with Bimekizumab.
Biperiden	The metabolism of Metamfetamine can be decreased when combined with Biperiden.
Bismuth subgallate	Metamfetamine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bismuth subnitrate	The serum concentration of Metamfetamine can be increased when it is combined with Bismuth subnitrate.
Bisoprolol	The therapeutic efficacy of Bisoprolol can be decreased when used in combination with Metamfetamine.
Bisoxatin	Metamfetamine may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Bitolterol	The risk or severity of hypertension can be increased when Bitolterol is combined with Metamfetamine.
Black cohosh	The metabolism of Metamfetamine can be decreased when combined with Black cohosh.
Bleomycin	Bleomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Bortezomib	The metabolism of Metamfetamine can be decreased when combined with Bortezomib.
Bosentan	Metamfetamine may decrease the antihypertensive activities of Bosentan.
Bretylium	The therapeutic efficacy of Bretylium can be decreased when used in combination with Metamfetamine.
Brexpiprazole	The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Metamfetamine.
Brivaracetam	Metamfetamine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Bromazepam	Bromazepam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Bromocriptine	The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Metamfetamine.
Bromodiphenh	Metamfetamine may decrease the sedative activities of Bromodiphenhydramine.
Bromotheophylline	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Bromotheophylline.
Bromperidol	Bromperidol may decrease the stimulatory activities of Metamfetamine.
Brompheniramine	Metamfetamine may decrease the sedative activities of Brompheniramine.
Buclizine	Metamfetamine may decrease the sedative activities of Buclizine.
Budesonide	Budesonide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Bumadizone	The risk or severity of hypertension can be increased when Metamfetamine is combined with Bumadizone.
Bumetanide	Bumetanide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Bupivacaine	The metabolism of Metamfetamine can be decreased when combined with Bupivacaine.
Buprenorphine	Metamfetamine may increase the analgesic activities of Buprenorphine.
Bupropion	The metabolism of Metamfetamine can be decreased when combined with Bupropion.
Buspirone	The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Metamfetamine.
Butabarbital	Butabarbital may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Butaperazine	Butaperazine may decrease the stimulatory activities of Metamfetamine.
Butorphanol	Metamfetamine may increase the analgesic activities of Butorphanol.
Butriptyline	Metamfetamine may decrease the sedative activities of Butriptyline.
Butylscopolamine	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Butylscopolamine.
Cabergoline	Cabergoline may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Caffeine	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Caffeine.
Calcium ascorbate	The serum concentration of Metamfetamine can be decreased when it is combined with Calcium ascorbate.
Calcium carbonate	The serum concentration of Metamfetamine can be increased when it is combined with Calcium carbonate.
Canagliflozin	Metamfetamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Canakinumab	The metabolism of Metamfetamine can be increased when combined with Canakinumab.
Candesartan cilexetil	Metamfetamine may decrease the antihypertensive activities of Candesartan cilexetil.
Cannabidiol	The metabolism of Metamfetamine can be decreased when combined with Cannabidiol.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	Capecitabine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Capreomycin	Metamfetamine may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Captopril	Metamfetamine may decrease the antihypertensive activities of Captopril.
Carbamazepine	Metamfetamine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
Carbidopa	Carbidopa may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Carbimazole	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Carbimazole.
Carbinoxamine	Metamfetamine may decrease the sedative activities of Carbinoxamine.
Carboplatin	Carboplatin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cariprazine	Cariprazine may decrease the stimulatory activities of Metamfetamine.
Carmustine	Carmustine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Caroxazone	Caroxazone may increase the hypertensive activities of Metamfetamine.
Carprofen	The risk or severity of hypertension can be increased when Carprofen is combined with Metamfetamine.
Carvedilol	The therapeutic efficacy of Carvedilol can be decreased when used in combination with Metamfetamine.
Cefaclor	Cefaclor may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefaloridine	Cefaloridine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefdinir	Cefdinir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.

Cefprozil	Cefprozil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefroxadine	Cefroxadine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ceftolozane	Metamfetamine may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Celecoxib	The metabolism of Metamfetamine can be decreased when combined with Celecoxib.
Celiprolol	The therapeutic efficacy of Celiprolol can be decreased when used in combination with Metamfetamine.
Cephalexin	Cephalexin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cerivastatin	The metabolism of Metamfetamine can be decreased when combined with Cerivastatin.
Certolizumab pegol	The metabolism of Metamfetamine can be increased when combined with Certolizumab pegol.
Cetirizine	Metamfetamine may decrease the sedative activities of Cetirizine.
Cevimeline	Cevimeline may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Chloral hydrate	Chloral hydrate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Chlorcyclizine	Metamfetamine may decrease the sedative activities of Chlorcyclizine.
Chloroquine	The metabolism of Metamfetamine can be decreased when combined with Chloroquine.
Chlorothiazide	Metamfetamine may decrease the antihypertensive activities of Chlorothiazide.
Chlorpheniramine	Metamfetamine may decrease the sedative activities of Chlorpheniramine.
Chlorphenoxamine	Metamfetamine may decrease the sedative activities of Chlorphenoxamine.
Chlorphentermine	The risk or severity of serotonin syndrome can be increased when Chlorphentermine is combined with Metamfetamine.
Chlorpromazine	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Chlorpromazine.
Chlorpropamide	Chlorpropamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Chlorprothixene	Metamfetamine may decrease the sedative activities of Chlorprothixene.
Chlorthalidone	Metamfetamine may decrease the antihypertensive activities of Chlorthalidone.
Chlorzoxazone	Chlorzoxazone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cholecalciferol	The metabolism of Metamfetamine can be decreased when combined with Cholecalciferol.
Choline C 11	Metamfetamine may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Choline magnesium	The risk or severity of hypertension can be increased when Choline magnesium trisalicylate is combined with Metamfetamine.
Choline salicylate	Metamfetamine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate	Metamfetamine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Metamfetamine may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Metamfetamine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Metamfetamine may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Metamfetamine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium	Metamfetamine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Metamfetamine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Ciclesonide	The metabolism of Metamfetamine can be decreased when combined with Ciclesonide.
Cidofovir	Cidofovir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cilazapril	Metamfetamine may decrease the antihypertensive activities of Cilazapril.
Cilostazol	Cilostazol may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cimetidine	Metamfetamine may decrease the sedative activities of Cimetidine.
Cinacalcet	The metabolism of Metamfetamine can be decreased when combined with Cinacalcet.
Cinnarizine	Metamfetamine may decrease the sedative activities of Cinnarizine.
Ciprofloxacin	Ciprofloxacin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cisapride	The metabolism of Metamfetamine can be decreased when combined with Cisapride.
Cisplatin	Metamfetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Citalopram	The metabolism of Citalopram can be decreased when combined with Metamfetamine.
Citric acid	The excretion of Metamfetamine can be decreased when combined with Citric acid.
Clemastine	Metamfetamine may decrease the sedative activities of Clemastine.
Clenbuterol	The risk or severity of hypertension can be increased when Clenbuterol is combined with Metamfetamine.
Clevidipine	Metamfetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Clidinium	The risk or severity of Tachycardia can be increased when Clidinium is combined with Metamfetamine.
Clobazam	The serum concentration of Metamfetamine can be increased when it is combined with Clobazam.
Clofarabine	Clofarabine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Clofedanol	Metamfetamine may decrease the sedative activities of Clofedanol.
Clomipramine	The therapeutic efficacy of Clomipramine can be increased when used in combination with Metamfetamine.
Clonazepam	Clonazepam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Clonidine	The metabolism of Clonidine can be decreased when combined with Metamfetamine.
Clorazepic acid	Clorazepic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Clothiapine	Clothiapine may decrease the stimulatory activities of Metamfetamine.
Clove oil	Metamfetamine may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	The serum concentration of Metamfetamine can be increased when it is combined with Clozapine.
Cobicistat	The metabolism of Metamfetamine can be decreased when combined with Cobicistat.
Cocaine	The metabolism of Metamfetamine can be decreased when combined with Cocaine.
Codeine	Metamfetamine may increase the analgesic activities of Codeine.
Colchicine	Colchicine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Colistimethate	Colistimethate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Colistin	Metamfetamine may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	Conivaptan may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Conjugated estrogens	Conjugated estrogens may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Corifollitropin alfa	Metamfetamine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Cryptenamine	Metamfetamine may decrease the antihypertensive activities of Cryptenamine.
Curcumin	The metabolism of Metamfetamine can be decreased when combined with Curcumin.
Cyanocobalamin	Cyanocobalamin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Cyclizine	Metamfetamine may decrease the sedative activities of Cyclizine.
Cyclobenzaprine	The risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with Metamfetamine.
Cyclopenthiazide	Metamfetamine may decrease the antihypertensive activities of Cyclopenthiazide.
Cyclosporine	The metabolism of Metamfetamine can be decreased when combined with Cyclosporine.
Cyclothiazide	Metamfetamine may decrease the antihypertensive activities of Cyclothiazide.
Cycrimine	The risk or severity of Tachycardia can be increased when Cycrimine is combined with Metamfetamine.
Cyproheptadine	Metamfetamine may decrease the sedative activities of Cyproheptadine.
Dabigatran	Metamfetamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Dacarbazine	Dacarbazine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Dacomitinib	The metabolism of Dacomitinib can be decreased when combined with Metamfetamine.
Dalfampridine	Metamfetamine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Daptomycin	Daptomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Darifenacin	The metabolism of Metamfetamine can be decreased when combined with Darifenacin.
Darunavir	The metabolism of Metamfetamine can be decreased when combined with Darunavir.
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Metamfetamine.
Dasiglucagon	Metamfetamine may decrease the antihypertensive activities of Dasiglucagon.
Debrisoquine	Metamfetamine may decrease the antihypertensive activities of Debrisoquine.
Deferiprone	Metamfetamine may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Delafloxacin	Metamfetamine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Delavirdine	The metabolism of Metamfetamine can be decreased when combined with Delavirdine.

Deserpidine	Metamfetamine may decrease the antihypertensive activities of Deserpidine.
Desflurane	The risk or severity of hypertension can be increased when Desflurane is combined with Metamfetamine.
Desipramine	Metamfetamine may decrease the sedative activities of Desipramine.
Desloratadine	Metamfetamine may decrease the sedative activities of Desloratadine.
Desmopressin	The risk or severity of hypertension can be increased when Desmopressin is combined with Metamfetamine.
Desvenlafaxine	The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Metamfetamine.
Deutetrabenazine	Metamfetamine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexbromphe	Metamfetamine may decrease the sedative activities of Dexbrompheniramine.
Dexchlorpheni	Metamfetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Dexetimide	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Dexetimide.
Dexfenfluramine	The risk or severity of serotonin syndrome can be increased when Dexfenfluramine is combined with Metamfetamine.
Dexibuprofen	The risk or severity of hypertension can be increased when Metamfetamine is combined with Dexibuprofen.
Dexketoprofen	The risk or severity of hypertension can be increased when Metamfetamine is combined with Dexketoprofen.
Dexmedetomidine	The metabolism of Metamfetamine can be decreased when combined with Dexmedetomidine.
Dexmethylphenidate	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Dexmethylphenidate.
Dexpanthenol	Metamfetamine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	Dexrazoxane may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Dextran	Metamfetamine may decrease the excretion rate of Dextran which could result in a higher serum level.
Dextroamphetamine	The risk or severity of serotonin syndrome can be increased when Dextroamphetamine is combined with Metamfetamine.
Dextromethorphan	The risk or severity of serotonin syndrome can be increased when Dextromethorphan is combined with Metamfetamine.
Dextropropoxyphene	Metamfetamine may increase the analgesic activities of Dextropropoxyphene.
Dezocine	Metamfetamine may increase the analgesic activities of Dezocine.
Diacerein	The metabolism of Metamfetamine can be decreased when combined with Diacerein.
Diamorphine	Metamfetamine may increase the analgesic activities of Diamorphine.
Diatrizoate	Diatrizoate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Diazepam	Diazepam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Diazoxide	Metamfetamine may decrease the antihypertensive activities of Diazoxide.
Dibenzepin	The therapeutic efficacy of Dibenzepin can be increased when used in combination with Metamfetamine.
Dichlorobenzyl	Metamfetamine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	The risk or severity of hypertension can be increased when Diclofenac is combined with Metamfetamine.
Diclofenamide	Diclofenamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Dicyclomine	Dicyclomine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Didanosine	Didanosine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Dienogest	Metamfetamine may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diethylpropion	The risk or severity of serotonin syndrome can be increased when Diethylpropion is combined with Metamfetamine.
Diflunisal	The risk or severity of hypertension can be increased when Diflunisal is combined with Metamfetamine.
Difluocortolone	Metamfetamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.
Digoxin	Metamfetamine may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydralazine	Metamfetamine may decrease the antihypertensive activities of Dihydralazine.
Dihydrocodeine	Metamfetamine may increase the analgesic activities of Dihydrocodeine.
Dihydroergocornine	Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Dihydroergocristine	The therapeutic efficacy of Dihydroergocristine can be decreased when used in combination with Metamfetamine.
Dihydroergotamine	The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Metamfetamine.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Diltiazem	Metamfetamine may decrease the antihypertensive activities of Diltiazem.
Dimenhydrinate	Metamfetamine may decrease the sedative activities of Dimenhydrinate.
Dimercaprol	Metamfetamine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimetacrine	The therapeutic efficacy of Dimetacrine can be increased when used in combination with Metamfetamine.
Dimethyl sulfoxide	The metabolism of Metamfetamine can be decreased when combined with Dimethyl sulfoxide.
Dimetindene	Metamfetamine may decrease the sedative activities of Dimetindene.
Dimetotiazine	Metamfetamine may decrease the sedative activities of Dimetotiazine.
Diphemanil	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Diphemanil.
Diphenhydramine	Metamfetamine may decrease the sedative activities of Diphenhydramine.
Diphenidol	The risk or severity of Tachycardia can be increased when Diphenidol is combined with Metamfetamine.
Diphenoxylate	Metamfetamine may increase the analgesic activities of Diphenoxylate.
Diphenylpyraline	Metamfetamine may decrease the sedative activities of Diphenylpyraline.
Disopyramide	Disopyramide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Disulfiram	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Disulfiram.
DL-Methylephedrine	The risk or severity of hypertension can be increased when Metamfetamine is combined with DL-Methylephedrine.
Dobutamine	The risk or severity of hypertension can be increased when Dobutamine is combined with Metamfetamine.
Dolasetron	The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Metamfetamine.
Domperidone	The metabolism of Metamfetamine can be decreased when combined with Domperidone.
Donepezil	The metabolism of Metamfetamine can be decreased when combined with Donepezil.
Dopamine	The metabolism of Dopamine can be decreased when combined with Metamfetamine.
Dopexamine	The risk or severity of hypertension can be increased when Metamfetamine is combined with Dopexamine.
Doripenem	Metamfetamine may decrease the excretion rate of Doripenem which could result in a higher serum level.
Dosulepin	Metamfetamine may decrease the sedative activities of Dosulepin.
Doxacurium	Doxacurium may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Doxapram	The risk or severity of hypertension can be increased when Doxapram is combined with Metamfetamine.
Doxazosin	The therapeutic efficacy of Doxazosin can be decreased when used in combination with Metamfetamine.
Doxepin	Metamfetamine may decrease the sedative activities of Doxepin.
Doxorubicin	The metabolism of Metamfetamine can be decreased when combined with Doxorubicin.
Doxycycline	Doxycycline may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Doxylamine	Metamfetamine may decrease the sedative activities of Doxylamine.
Dronabinol	The metabolism of Metamfetamine can be decreased when combined with Dronabinol.
Dronedarone	The metabolism of Metamfetamine can be decreased when combined with Dronedarone.
Droperidol	The therapeutic efficacy of Droperidol can be decreased when used in combination with Metamfetamine.
Drospirenone	Drospirenone may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Droxicam	The risk or severity of hypertension can be increased when Metamfetamine is combined with Droxicam.
Droxidopa	The therapeutic efficacy of Metamfetamine can be increased when used in combination with Droxidopa.
Duloxetine	The metabolism of Metamfetamine can be decreased when combined with Duloxetine.
Dutasteride	The therapeutic efficacy of Dutasteride can be decreased when used in combination with Metamfetamine.
Dyphylline	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Dyphylline.
Ebastine	Metamfetamine may decrease the sedative activities of Ebastine.
Edoxaban	Metamfetamine may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Edrophonium may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Elagolix	The metabolism of Elagolix can be decreased when combined with Metamfetamine.
Eletriptan	The risk or severity of serotonin syndrome can be increased when Eletriptan is combined with Metamfetamine.
Eliglustat	The metabolism of Metamfetamine can be decreased when combined with Eliglustat.
Eluxadoline	Metamfetamine may increase the analgesic activities of Eluxadoline.
Emapalumab	The metabolism of Metamfetamine can be increased when combined with Emapalumab.
Emedastine	Metamfetamine may decrease the sedative activities of Emedastine.
Enalapril	Metamfetamine may decrease the antihypertensive activities of Enalapril.
Enalaprilat	Metamfetamine may decrease the antihypertensive activities of Enalaprilat.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Metamfetamine.
Encainide	The metabolism of Metamfetamine can be decreased when combined with Encainide.
Encorafenib	The metabolism of Metamfetamine can be decreased when combined with Encorafenib.
Entacapone	The metabolism of Metamfetamine can be decreased when combined with Entacapone.
Enzalutamide	Metamfetamine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Ephedra sinica	The risk or severity of hypertension can be increased when Ephedra sinica root is combined with Metamfetamine.

Ephedrine	The therapeutic efficacy of Metamfetamine can be increased when used in combination with Ephedrine.
Epinastine	Metamfetamine may decrease the sedative activities of Epinastine.
Epinephrine	The therapeutic efficacy of Metamfetamine can be increased when used in combination with Epinephrine.
Eplerenone	Metamfetamine may decrease the antihypertensive activities of Eplerenone.
Epoprostenol	Metamfetamine may decrease the antihypertensive activities of Epoprostenol.
Eprosartan	Metamfetamine may decrease the antihypertensive activities of Eprosartan.
Eravacycline	The metabolism of Eravacycline can be decreased when combined with Metamfetamine.
Ergoloid mes	The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Metamfetamine.
Ergometrine	Ergometrine may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Ergotamine	The therapeutic efficacy of Ergotamine can be decreased when used in combination with Metamfetamine.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Metamfetamine.
Ertapenem	Ertapenem may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Escitalopram	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Escitalopram.
Esketamine	The risk or severity of hypertension can be increased when Esketamine is combined with Metamfetamine.
Esmolol	The therapeutic efficacy of Esmolol can be decreased when used in combination with Metamfetamine.
Estazolam	Estazolam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Estradiol	Estradiol may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Estradiol acetate	Metamfetamine may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypi	Metamfetamine may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate	Metamfetamine may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate	Metamfetamine may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Estrone sulfate	Metamfetamine may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Eszopiclone	Eszopiclone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Etafedrine	The risk or severity of hypertension can be increased when Metamfetamine is combined with Etafedrine.
Etanercept	The metabolism of Metamfetamine can be increased when combined with Etanercept.
Ethambutol	Ethambutol may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ethosuximide	Metamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ethoxzolamide	Ethoxzolamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Etilefrine	The risk or severity of hypertension can be increased when Metamfetamine is combined with Etilefrine.
Etodolac	The risk or severity of hypertension can be increased when Etodolac is combined with Metamfetamine.
Etomidate	The risk or severity of hypertension can be increased when Etomidate is combined with Metamfetamine.
Etonogestrel	Etonogestrel may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Etoperidone	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Etoperidone.
Etoricoxib	The risk or severity of hypertension can be increased when Metamfetamine is combined with Etoricoxib.
Eucalyptus oil	Metamfetamine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Evening primro	Metamfetamine may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Everolimus	The metabolism of Metamfetamine can be decreased when combined with Everolimus.
Ezogabine	Metamfetamine may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Famotidine	Metamfetamine may decrease the sedative activities of Famotidine.
Fedratinib	The serum concentration of Metamfetamine can be increased when it is combined with Fedratinib.
Felodipine	The metabolism of Metamfetamine can be decreased when combined with Felodipine.
Fenbufen	The risk or severity of hypertension can be increased when Metamfetamine is combined with Fenbufen.
Fenfluramine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Fenfluramine.
Fenofibrate	Fenofibrate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fenofibric acid	Metamfetamine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	Metamfetamine may decrease the antihypertensive activities of Fenoldopam.
Fenoprofen	The risk or severity of hypertension can be increased when Fenoprofen is combined with Metamfetamine.
Fenoterol	The risk or severity of hypertension can be increased when Fenoterol is combined with Metamfetamine.
Fenproporex	Fenproporex may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fentanyl	Metamfetamine may increase the analgesic activities of Fentanyl.
Ferrous ascorbate	The serum concentration of Metamfetamine can be decreased when it is combined with Ferrous ascorbate.
Fesoterodine	Metamfetamine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Fexinidazole	The metabolism of Fexinidazole can be decreased when combined with Metamfetamine.
Fexofenadine	Metamfetamine may decrease the sedative activities of Fexofenadine.
Finasteride	The risk or severity of hypertension can be increased when Finasteride is combined with Metamfetamine.
Finerenone	Finerenone may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Flavoxate	Flavoxate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Flecainide	The metabolism of Flecainide can be decreased when combined with Metamfetamine.
Flibanserin	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Flibanserin.
Floctafenine	The risk or severity of hypertension can be increased when Metamfetamine is combined with Floctafenine.
Florbetaben F	Metamfetamine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir F-18	Metamfetamine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	Floxuridine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fluconazole	Fluconazole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Flucytosine	Flucytosine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fludeoxyglucose	Metamfetamine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Flumazenil	Flumazenil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Flunarizine	Metamfetamine may decrease the sedative activities of Flunarizine.
Fluocinolone	Fluocinolone acetonide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fluoxetine	The serum concentration of Metamfetamine can be increased when it is combined with Fluoxetine.
Flupentixol	The therapeutic efficacy of Flupentixol can be decreased when used in combination with Metamfetamine.
Fluphenazine	Fluphenazine may decrease the stimulatory activities of Metamfetamine.
Flurazepam	Flurazepam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Flurbiprofen	The risk or severity of hypertension can be increased when Flurbiprofen is combined with Metamfetamine.
Fluspirilene	Fluspirilene may decrease the stimulatory activities of Metamfetamine.
Flutamide	Flutamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fluvastatin	The metabolism of Metamfetamine can be decreased when combined with Fluvastatin.
Fluvoxamine	The metabolism of Metamfetamine can be decreased when combined with Fluvoxamine.
Folic acid	Folic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Follitropin	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Follitropin.
Fomepizole	Fomepizole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fondaparinux	Fondaparinux may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Formestane	Metamfetamine may decrease the excretion rate of Formestane which could result in a higher serum level.
Formoterol	Metamfetamine may increase the sympathomimetic activities of Formoterol.
Foscarnet	Foscarnet may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fosfomycin	Fosfomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Fosinopril	Metamfetamine may decrease the antihypertensive activities of Fosinopril.
Fosphenytoin	The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Metamfetamine.
Framycetin	Framycetin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Frovatriptan	The risk or severity of serotonin syndrome can be increased when Frovatriptan is combined with Metamfetamine.
Furosemide	Metamfetamine may decrease the antihypertensive activities of Furosemide.
Fusidic acid	The metabolism of Metamfetamine can be decreased when combined with Fusidic acid.
Gabapentin	Metamfetamine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	Gadobenic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Gadofosveset	Metamfetamine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Gadopentetic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Gadoteric acid	Metamfetamine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Gadoteridol may decrease the excretion rate of Metamfetamine which could result in a higher serum level.

Galantamine	The metabolism of Metamfetamine can be decreased when combined with Galantamine.
Gallamine triethi	The risk or severity of Tachycardia can be increased when Gallamine triethiodide is combined with Metamfetamine.
Ganciclovir	Ganciclovir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Gefitinib	The metabolism of Metamfetamine can be decreased when combined with Gefitinib.
Gemcitabine	Gemcitabine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Gemfibrozil	Gemfibrozil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Gentamicin	Metamfetamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gepirone	The risk or severity of serotonin syndrome can be increased when Gepirone is combined with Metamfetamine.
Gimeracil	Metamfetamine may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	The serum concentration of Metamfetamine can be increased when it is combined with Givosiran.
Glipizide	Glipizide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Glutamic acid	The serum concentration of Metamfetamine can be decreased when it is combined with Glutamic acid.
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Metamfetamine.
Glycerol phenylb	The metabolism of Metamfetamine can be decreased when combined with Glycerol phenylbutyrate.
Glycopyrronium	The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Metamfetamine.
Golimumab	The metabolism of Metamfetamine can be increased when combined with Golimumab.
Golodirsen	Metamfetamine may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Granisetron	The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Metamfetamine.
Guanabenz	Metamfetamine may decrease the antihypertensive activities of Guanabenz.
Guanadrel	The therapeutic efficacy of Guanadrel can be decreased when used in combination with Metamfetamine.
Guanethidine	The serum concentration of Metamfetamine can be decreased when it is combined with Guanethidine.
Guanfacine	Metamfetamine may decrease the antihypertensive activities of Guanfacine.
Guanoxan	Metamfetamine may decrease the antihypertensive activities of Guanoxan.
Halofantrine	The metabolism of Metamfetamine can be decreased when combined with Halofantrine.
Haloperidol	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Haloperidol.
Halothane	The risk or severity of hypertension can be increased when Halothane is combined with Metamfetamine.
Hexocyclium	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Hexocyclium.
Hexoprenaline	The risk or severity of hypertension can be increased when Metamfetamine is combined with Hexoprenaline.
Homatropine	The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Metamfetamine.
Hydralazine	Metamfetamine may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide	Metamfetamine may decrease the antihypertensive activities of Hydrochlorothiazide.
Hydrocodone	The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Metamfetamine.
Hydroflumethiazide	Metamfetamine may decrease the antihypertensive activities of Hydroflumethiazide.
Hydromorphone	Metamfetamine may increase the analgesic activities of Hydromorphone.
Hydrotalcite	The serum concentration of Metamfetamine can be increased when it is combined with Hydrotalcite.
Hydroxocobalamin	Hydroxocobalamin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Hydroxychloroquine	The metabolism of Metamfetamine can be decreased when combined with Hydroxychloroquine.
Hydroxyethyl Starch	Metamfetamine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyzine	Metamfetamine may decrease the sedative activities of Hydroxyzine.
Hyoscyamine	The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Metamfetamine.
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Metamfetamine.
Ibuprofen	The risk or severity of hypertension can be increased when Ibuprofen is combined with Metamfetamine.
Ibuproxam	The risk or severity of hypertension can be increased when Metamfetamine is combined with Ibuproxam.
Ibutilide	Ibutilide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Icatibant	Metamfetamine may decrease the excretion rate of Icatibant which could result in a higher serum level.
Icosapent	The risk or severity of hypertension can be increased when Icosapent is combined with Metamfetamine.
Idarubicin	The metabolism of Metamfetamine can be decreased when combined with Idarubicin.
Idarucizumab	Metamfetamine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Metamfetamine may decrease the excretion rate of Idebenone which could result in a higher serum level.
Ifenprodil	The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Metamfetamine.
Ifosfamide	Ifosfamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Iloperidone	Metamfetamine may decrease the sedative activities of Iloperidone.
Imatinib	The serum concentration of Metamfetamine can be increased when it is combined with Imatinib.
Imipramine	Metamfetamine may decrease the sedative activities of Imipramine.
Indacaterol	The risk or severity of hypertension can be increased when Metamfetamine is combined with Indacaterol.
Indalpine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Indalpine.
Indapamide	Metamfetamine may decrease the antihypertensive activities of Indapamide.
Indenolol	The therapeutic efficacy of Indenolol can be decreased when used in combination with Metamfetamine.
Indigotindisulfonic acid	Metamfetamine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indomethacin	The risk or severity of hypertension can be increased when Indomethacin is combined with Metamfetamine.
Indoprofen	The risk or severity of hypertension can be increased when Metamfetamine is combined with Indoprofen.
Indoramin	The therapeutic efficacy of Indoramin can be decreased when used in combination with Metamfetamine.
Infliximab	The metabolism of Metamfetamine can be increased when combined with Infliximab.
Inosine pranobex	Metamfetamine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Inositol	Metamfetamine may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen	Inotersen may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Iobenguane	Metamfetamine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iobenguane sulfa	Metamfetamine may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol	Iodixanol may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Iofetamine I-123	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Iofetamine I-123.
Ioflupane I-123	Metamfetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.
Iopromide	Metamfetamine may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid	Metamfetamine may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol	Metamfetamine may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan	Metamfetamine may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Ipecac	Metamfetamine may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab	Metamfetamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Ipratropium	The risk or severity of Tachycardia can be increased when Ipratropium is combined with Metamfetamine.
Iproniazid	Iproniazid may increase the hypertensive activities of Metamfetamine.
Iptacopan	The metabolism of Iptacopan can be decreased when combined with Metamfetamine.
Irbesartan	Metamfetamine may decrease the antihypertensive activities of Irbesartan.
Isavuconazole	The metabolism of Metamfetamine can be decreased when combined with Isavuconazole.
Isavuconazonium	The metabolism of Metamfetamine can be decreased when combined with Isavuconazonium.
Isocarboxazid	Isocarboxazid may increase the hypertensive activities of Metamfetamine.
Isoetharine	The risk or severity of hypertension can be increased when Isoetharine is combined with Metamfetamine.
Isoflavone	Metamfetamine may decrease the excretion rate of Isoflavone which could result in a higher serum level.
Isoflurane	The risk or severity of hypertension can be increased when Isoflurane is combined with Metamfetamine.
Isometheptene	The risk or severity of hypertension can be increased when Metamfetamine is combined with Isometheptene.
Isoniazid	The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Metamfetamine.
Isoprenaline	The risk or severity of hypertension can be increased when Isoprenaline is combined with Metamfetamine.
Isopropamide	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Isopropamide.
Isosorbide	Isosorbide may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide mononitrate	Isosorbide mononitrate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Isosulfan blue	Metamfetamine may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin	Isotretinoin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Isoxicam	The risk or severity of hypertension can be increased when Metamfetamine is combined with Isoxicam.
Isoxsuprine	The risk or severity of hypertension can be increased when Metamfetamine is combined with Isoxsuprine.
Isradipine	Metamfetamine may decrease the antihypertensive activities of Isradipine.
Istradefylline	The metabolism of Istradefylline can be decreased when combined with Metamfetamine.

Ixazomib	Metamfetamine may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Kanamycin	Metamfetamine may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	Ketamine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ketazolam	Metamfetamine may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Ketoconazole	The metabolism of Metamfetamine can be decreased when combined with Ketoconazole.
Ketoprofen	The risk or severity of hypertension can be increased when Ketoprofen is combined with Metamfetamine.
Ketorolac	The risk or severity of hypertension can be increased when Ketorolac is combined with Metamfetamine.
Ketotifen	Metamfetamine may decrease the sedative activities of Ketotifen.
L-tartaric acid	The excretion of Metamfetamine can be decreased when combined with L-tartaric acid.
Labetalol	The therapeutic efficacy of Labetalol can be decreased when used in combination with Metamfetamine.
Lacidipine	Metamfetamine may decrease the antihypertensive activities of Lacidipine.
Lamivudine	Lamivudine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Lamotrigine	The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Metamfetamine.
Landiolol	The therapeutic efficacy of Landiolol can be decreased when used in combination with Metamfetamine.
Lansoprazole	The metabolism of Metamfetamine can be decreased when combined with Lansoprazole.
Lasmiditan	The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Metamfetamine.
Latamoxef	Latamoxef may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ledipasvir	Metamfetamine may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Lenalidomide	Lenalidomide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Lercanidipine	Metamfetamine may decrease the antihypertensive activities of Lercanidipine.
Lesinurad	Metamfetamine may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Leuprolide	Leuprolide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Levacetylmethadol	Metamfetamine may increase the analgesic activities of Levacetylmethadol.
Levamlodipine	Metamfetamine may decrease the antihypertensive activities of Levamlodipine.
Levobetaxolol	The therapeutic efficacy of Levobetaxolol can be decreased when used in combination with Metamfetamine.
Levobupivacaine	Levobupivacaine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Levocarnitine	Levocarnitine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Levocetirizine	Metamfetamine may decrease the sedative activities of Levocetirizine.
Levodopa	The risk or severity of serotonin syndrome can be increased when Levodopa is combined with Metamfetamine.
Levofloxacin	Levofloxacin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Levomilnacipran	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Levomilnacipran.
Levonordefrin	The therapeutic efficacy of Metamfetamine can be increased when used in combination with Levonordefrin.
Levorphanol	Metamfetamine may increase the analgesic activities of Levorphanol.
Levosalbutamol	The risk or severity of hypertension can be increased when Metamfetamine is combined with Levosalbutamol.
Levothyroxine	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Levothyroxine.
Lidocaine	The metabolism of Metamfetamine can be decreased when combined with Lidocaine.
Linezolid	The risk or severity of hypertension can be increased when Linezolid is combined with Metamfetamine.
Liothyronine	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Liothyronine.
Liotrix	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Liotrix.
Lisdexamfetamine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Lisdexamfetamine.
Lisinopril	Metamfetamine may decrease the antihypertensive activities of Lisinopril.
Lisuride	Lisuride may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Lithium carbonate	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Lithium carbonate.
Lithium cation	Lithium cation may decrease the stimulatory activities of Metamfetamine.
Lithium citrate	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Lithium citrate.
Lithium hydroxide	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Lithium hydroxide.
Lixisenatide	Metamfetamine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Lofexidine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Lofexidine.
Lomifylline	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Lomifylline.
Lopinavir	Lopinavir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Loracarbef	Loracarbef may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Loratadine	Metamfetamine may decrease the sedative activities of Loratadine.
Lorazepam	Lorazepam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Lorcaserin	The metabolism of Metamfetamine can be decreased when combined with Lorcaserin.
Lornoxicam	The risk or severity of hypertension can be increased when Metamfetamine is combined with Lornoxicam.
Lorpiprazole	Metamfetamine may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Losartan	Metamfetamine may decrease the antihypertensive activities of Losartan.
Loxapine	Loxapine may decrease the stimulatory activities of Metamfetamine.
Loxoprofen	The risk or severity of hypertension can be increased when Metamfetamine is combined with Loxoprofen.
Lubiprostone	Lubiprostone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Lumateperone	Lumateperone may decrease the stimulatory activities of Metamfetamine.
Lumefantrine	The metabolism of Metamfetamine can be decreased when combined with Lumefantrine.
Lumiracoxib	The risk or severity of hypertension can be increased when Lumiracoxib is combined with Metamfetamine.
Lurasidone	The therapeutic efficacy of Lurasidone can be decreased when used in combination with Metamfetamine.
Macitentan	Metamfetamine may decrease the antihypertensive activities of Macitentan.
Magaldrate	The serum concentration of Metamfetamine can be increased when it is combined with Magaldrate.
Magnesium asco	The serum concentration of Metamfetamine can be decreased when it is combined with Magnesium ascorbate.
Magnesium carbo	The serum concentration of Metamfetamine can be increased when it is combined with Magnesium carbonate.
Magnesium chloride	Metamfetamine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium hydroxide	The serum concentration of Metamfetamine can be increased when it is combined with Magnesium hydroxide.
Magnesium oxide	The serum concentration of Metamfetamine can be increased when it is combined with Magnesium oxide.
Magnesium salicylate	The risk or severity of hypertension can be increased when Magnesium salicylate is combined with Metamfetamine.
Magnesium silicate	The serum concentration of Metamfetamine can be increased when it is combined with Magnesium silicate.
Magnesium trisilicate	The serum concentration of Metamfetamine can be increased when it is combined with Magnesium trisilicate.
Mangafodipir	Metamfetamine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Manidipine	The metabolism of Metamfetamine can be decreased when combined with Manidipine.
Mannitol	Mannitol may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Maprotiline	Metamfetamine may decrease the sedative activities of Maprotiline.
Mavorixafor	The metabolism of Metamfetamine can be decreased when combined with Mavorixafor.
Mazindol	The risk or severity of serotonin syndrome can be increased when Mazindol is combined with Metamfetamine.
Mebanazine	Mebanazine may increase the hypertensive activities of Metamfetamine.
Mebeverine	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Mebeverine.
Mecamylamine	Metamfetamine may decrease the antihypertensive activities of Mecamylamine.
Meclizine	Metamfetamine may decrease the sedative activities of Meclizine.
Meclofenamic acid	The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Metamfetamine.
Medroxyprogeste	Medroxyprogesterone acetate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Mefenamic acid	The risk or severity of hypertension can be increased when Mefenamic acid is combined with Metamfetamine.
Megestrol acetate	Megestrol acetate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Meloxicam	The risk or severity of hypertension can be increased when Meloxicam is combined with Metamfetamine.
Memantine	Memantine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Mepenzolate	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Mepenzolate.
Meperidine	The therapeutic efficacy of Meperidine can be increased when used in combination with Metamfetamine.
Mephentermine	The risk or severity of serotonin syndrome can be increased when Mephentermine is combined with Metamfetamine.
Mephenytoin	The metabolism of Metamfetamine can be decreased when combined with Mephenytoin.
Mepivacaine	Mepivacaine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Mepyramine	Metamfetamine may decrease the sedative activities of Mepyramine.
Mercaptopurine	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Mercaptopurine.
Meropenem	Meropenem may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Mesalazine	The risk or severity of hypertension can be increased when Mesalazine is combined with Metamfetamine.
Mesoridazine	Mesoridazine may decrease the stimulatory activities of Metamfetamine.

Metamizole	The risk or severity of hypertension can be increased when Metamfetamine is combined with Metamizole.
Metaraminol	The risk or severity of hypertension can be increased when Metaraminol is combined with Metamfetamine.
Metaxalone	The risk or severity of serotonin syndrome can be increased when Metaxalone is combined with Metamfetamine.
Metergoline	Metergoline may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Metformin	Metformin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Methadone	Metamfetamine may increase the analgesic activities of Methadone.
Methantheline	Metamfetamine may decrease the sedative activities of Methantheline.
Methapyrilene	Metamfetamine may decrease the sedative activities of Methapyrilene.
Methazolamide	Methazolamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Methdilazine	Metamfetamine may decrease the sedative activities of Methdilazine.
Methenamine	The serum concentration of Metamfetamine can be decreased when it is combined with Methenamine.
Methimazole	The metabolism of Metamfetamine can be decreased when combined with Methimazole.
Methotrexate	Methotrexate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Methotrimeprazine	Metamfetamine may decrease the sedative activities of Methotrimeprazine.
Methoxamine	The risk or severity of hypertension can be increased when Methoxamine is combined with Metamfetamine.
Methoxsalen	Methoxsalen may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Methoxyflurane	The risk or severity of hypertension can be increased when Methoxyflurane is combined with Metamfetamine.
Methoxyphenamine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Methoxyphenamine.
Methscopolamine	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Methscopolamine.
Methscopolamine	The risk or severity of Tachycardia can be increased when Methscopolamine bromide is combined with Metamfetamine.
Methyclothiazide	Methyclothiazide may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Methyldopa	Metamfetamine may decrease the antihypertensive activities of Methyldopa.
Methylene blue	Metamfetamine may increase the serotonergic activities of Methylene blue.
Methylergometrine	Methylergometrine may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Methylnaltrexone	Metamfetamine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methylphenidate	The risk or severity of hypertension can be increased when Methylphenidate is combined with Metamfetamine.
Methylphenobarbital	The serum concentration of Methylphenobarbital can be decreased when it is combined with Metamfetamine.
Methyltestosterone	Metamfetamine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Methysergide	Methysergide may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Meticrane	Meticrane may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Metixene	The risk or severity of Tachycardia can be increased when Metixene is combined with Metamfetamine.
Metoclopramide	The metabolism of Metamfetamine can be decreased when combined with Metoclopramide.
Metocurine	The risk or severity of Tachycardia can be increased when Metocurine is combined with Metamfetamine.
Metolazone	Metamfetamine may decrease the antihypertensive activities of Metolazone.
Metoprolol	The metabolism of Metamfetamine can be decreased when combined with Metoprolol.
Metyrapone	Metyrapone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metyrosine	Metamfetamine may decrease the antihypertensive activities of Metyrosine.
Mexiletine	The metabolism of Metamfetamine can be decreased when combined with Mexiletine.
Mianserin	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Mianserin.
Mibefradil	The metabolism of Metamfetamine can be decreased when combined with Mibefradil.
Miconazole	The metabolism of Metamfetamine can be decreased when combined with Miconazole.
Midazolam	Midazolam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Midodrine	The risk or severity of hypertension can be increased when Midodrine is combined with Metamfetamine.
Mifepristone	The metabolism of Metamfetamine can be decreased when combined with Mifepristone.
Migalastat	Metamfetamine may decrease the excretion rate of Migalastat which could result in a higher serum level.
Milnacipran	Milnacipran may increase the tachycardic activities of Metamfetamine.
Milrinone	Milrinone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Minaprine	Minaprine may increase the hypertensive activities of Metamfetamine.
Minoxidil	Metamfetamine may decrease the antihypertensive activities of Minoxidil.
Mirabegron	The serum concentration of Metamfetamine can be increased when it is combined with Mirabegron.
Mirtazapine	Metamfetamine may increase the serotonergic activities of Mirtazapine.
Mivacurium	The risk or severity of Tachycardia can be increased when Mivacurium is combined with Metamfetamine.
Mizolastine	Metamfetamine may decrease the sedative activities of Mizolastine.
Moclobemide	Moclobemide may increase the hypertensive activities of Metamfetamine.
Modafinil	The risk or severity of hypertension can be increased when Metamfetamine is combined with Modafinil.
Moexipril	Metamfetamine may decrease the antihypertensive activities of Moexipril.
Molindone	Molindone may decrease the stimulatory activities of Metamfetamine.
Moricizine	Moricizine may decrease the stimulatory activities of Metamfetamine.
Morphine	Metamfetamine may increase the analgesic activities of Morphine.
Moxisylyte	The therapeutic efficacy of Moxisylyte can be decreased when used in combination with Metamfetamine.
Moxonidine	Metamfetamine may decrease the antihypertensive activities of Moxonidine.
Muzolimine	Metamfetamine may decrease the antihypertensive activities of Muzolimine.
Mycophenolate	Mycophenolate mofetil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Mycophenolic acid	Mycophenolic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
N-acetyltyrosine	Metamfetamine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabilone	The risk or severity of Tachycardia can be increased when Nabilone is combined with Metamfetamine.
Nabumetone	The risk or severity of hypertension can be increased when Nabumetone is combined with Metamfetamine.
Nadolol	The therapeutic efficacy of Nadolol can be decreased when used in combination with Metamfetamine.
Nalbuphine	Metamfetamine may increase the analgesic activities of Nalbuphine.
Naldemedine	Metamfetamine may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene	Metamfetamine may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Naloxegol	Metamfetamine may increase the analgesic activities of Naloxegol.
Naloxone	Naloxone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Naltrexone	Metamfetamine may increase the analgesic activities of Naltrexone.
Naphazoline	The risk or severity of hypertension can be increased when Metamfetamine is combined with Naphazoline.
Naproxen	The risk or severity of hypertension can be increased when Naproxen is combined with Metamfetamine.
Naratriptan	The metabolism of Naratriptan can be decreased when combined with Metamfetamine.
Nateglinide	Nateglinide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Naxitamab	The risk or severity of hypertension can be increased when Metamfetamine is combined with Naxitamab.
Nebivolol	The therapeutic efficacy of Nebivolol can be decreased when used in combination with Metamfetamine.
Nedaplatin	Metamfetamine may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Nedocromil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Nefazodone	The therapeutic efficacy of Nefazodone can be decreased when used in combination with Metamfetamine.
Neomycin	Metamfetamine may decrease the excretion rate of Neomycin which could result in a higher serum level.
Netilmicin	Metamfetamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Netupitant	The metabolism of Netupitant can be decreased when combined with Metamfetamine.
Nevirapine	The metabolism of Metamfetamine can be decreased when combined with Nevirapine.
Niacin	The metabolism of Metamfetamine can be decreased when combined with Niacin.
Niacinamide ascorbate	The serum concentration of Metamfetamine can be decreased when it is combined with Niacinamide ascorbate.
Nialamide	Nialamide may increase the hypertensive activities of Metamfetamine.
Nicardipine	The metabolism of Metamfetamine can be decreased when combined with Nicardipine.
Nicergoline	The therapeutic efficacy of Nicergoline can be decreased when used in combination with Metamfetamine.
Nicorandil	Metamfetamine may decrease the antihypertensive activities of Nicorandil.
Nicotine	The risk or severity of Tachycardia can be increased when Nicotine is combined with Metamfetamine.
Nifedipine	Nifedipine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Nilutamide	Nilutamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Nilvadipine	Metamfetamine may decrease the antihypertensive activities of Nilvadipine.
Nimesulide	The risk or severity of hypertension can be increased when Metamfetamine is combined with Nimesulide.
Nimodipine	Metamfetamine may decrease the antihypertensive activities of Nimodipine.
Nirogacestat	The metabolism of Nirogacestat can be decreased when combined with Metamfetamine.

Nisoldipine	Metamfetamine may decrease the antihypertensive activities of Nisoldipine.
Nitrendipine	Metamfetamine may decrease the antihypertensive activities of Nitrendipine.
Nitric Oxide	Nitric Oxide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Nitroglycerin	Metamfetamine may decrease the antihypertensive activities of Nitroglycerin.
Nitroprusside	Metamfetamine may decrease the antihypertensive activities of Nitroprusside.
Nitrous oxide	The risk or severity of hypertension can be increased when Metamfetamine is combined with Nitrous oxide.
Nizatidine	Metamfetamine may decrease the sedative activities of Nizatidine.
Norepinephrine	The therapeutic efficacy of Metamfetamine can be increased when used in combination with Norepinephrine.
Normethadone	Metamfetamine may increase the analgesic activities of Normethadone.
Nortriptyline	Metamfetamine may decrease the sedative activities of Nortriptyline.
Nylidrin	The risk or severity of hypertension can be increased when Metamfetamine is combined with Nylidrin.
Octamoxin	Octamoxin may increase the hypertensive activities of Metamfetamine.
Octinoxate	Metamfetamine may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Olanzapine	Metamfetamine may decrease the sedative activities of Olanzapine.
Oliceridine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Oliceridine.
Olmesartan	Metamfetamine may decrease the antihypertensive activities of Olmesartan.
Olodaterol	The risk or severity of hypertension can be increased when Metamfetamine is combined with Olodaterol.
Olsalazine	Olsalazine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ondansetron	The risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Metamfetamine.
Opium	Metamfetamine may increase the analgesic activities of Opium.
Orciprenaline	The risk or severity of hypertension can be increased when Orciprenaline is combined with Metamfetamine.
Oritavancin	The metabolism of Metamfetamine can be decreased when combined with Oritavancin.
Orphenadrine	Metamfetamine may decrease the sedative activities of Orphenadrine.
Oseltamivir	Oseltamivir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Osilodrostat	The metabolism of Metamfetamine can be decreased when combined with Osilodrostat.
Ospemifene	The metabolism of Metamfetamine can be decreased when combined with Ospemifene.
Oxacillin	Oxacillin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Oxamniquine	The metabolism of Metamfetamine can be decreased when combined with Oxamniquine.
Oxaprozin	The risk or severity of hypertension can be increased when Oxaprozin is combined with Metamfetamine.
Oxatomide	Metamfetamine may decrease the sedative activities of Oxatomide.
Oxazepam	Oxazepam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Oxprenolol	The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Metamfetamine.
Oxtriphylline	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Oxtriphylline.
Oxybenzone	Oxybenzone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Oxybutynin	The metabolism of Metamfetamine can be decreased when combined with Oxybutynin.
Oxycodone	Metamfetamine may increase the analgesic activities of Oxycodone.
Oxymetazoline	The risk or severity of hypertension can be increased when Oxymetazoline is combined with Metamfetamine.
Oxymorphone	Metamfetamine may increase the analgesic activities of Oxymorphone.
Oxyphenbutazone	The risk or severity of hypertension can be increased when Metamfetamine is combined with Oxyphenbutazone.
Oxyphencyclimine	The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Metamfetamine.
Oxyphenonium	The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Metamfetamine.
Oxyquinoline	Metamfetamine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Paliperidone	The therapeutic efficacy of Paliperidone can be decreased when used in combination with Metamfetamine.
Palonosetron	The risk or severity of serotonin syndrome can be increased when Palonosetron is combined with Metamfetamine.
Palopegteriparatide	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Palopegteriparatide.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Pancuronium	The risk or severity of Tachycardia can be increased when Pancuronium is combined with Metamfetamine.
Panobinostat	The metabolism of Metamfetamine can be decreased when combined with Panobinostat.
Pantoprazole	Pantoprazole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Parathyroid horm	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Parathyroid hormone.
Parecoxib	The risk or severity of hypertension can be increased when Metamfetamine is combined with Parecoxib.
Pargyline	Pargyline may increase the hypertensive activities of Metamfetamine.
Paromomycin	Paromomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Paroxetine	The metabolism of Metamfetamine can be decreased when combined with Paroxetine.
Patent Blue	Metamfetamine may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The metabolism of Metamfetamine can be decreased when combined with Pazopanib.
Pegaptanib	Metamfetamine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Peginesatide	Metamfetamine may decrease the excretion rate of Peginesatide which could result in a higher serum level.
Peginterferon alfa-	The metabolism of Metamfetamine can be decreased when combined with Peginterferon alfa-2b.
Pemetrexed	Metamfetamine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Penbutolol	The therapeutic efficacy of Penbutolol can be decreased when used in combination with Metamfetamine.
Pentaerythritol	Metamfetamine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Pentamidine	Pentamidine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Pentastarch	Metamfetamine may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentazocine	Metamfetamine may increase the analgesic activities of Pentazocine.
Pentetic acid	Metamfetamine may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	Pentobarbital may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Pentolinium	Metamfetamine may decrease the antihypertensive activities of Pentolinium.
Pentostatin	Metamfetamine may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Pentoxifylline	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Pentoxifylline.
Perazine	Perazine may decrease the stimulatory activities of Metamfetamine.
Pergolide	Pergolide may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Perhexiline	The metabolism of Metamfetamine can be decreased when combined with Perhexiline.
Periciazine	The therapeutic efficacy of Periciazine can be decreased when used in combination with Metamfetamine.
Perindopril	Metamfetamine may decrease the antihypertensive activities of Perindopril.
Permethrin	Metamfetamine may decrease the excretion rate of Permethrin which could result in a higher serum level.
Perphenazine	Perphenazine may decrease the stimulatory activities of Metamfetamine.
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Metamfetamine.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Phendimetrazine	The risk or severity of hypertension can be increased when Metamfetamine is combined with Phendimetrazine.
Phenelzine	Phenelzine may increase the hypertensive activities of Metamfetamine.
Phenformin	The metabolism of Metamfetamine can be decreased when combined with Phenformin.
Phenindamine	Metamfetamine may decrease the sedative activities of Phenindamine.
Pheniprazine	Pheniprazine may increase the hypertensive activities of Metamfetamine.
Pheniramine	Metamfetamine may decrease the sedative activities of Pheniramine.
Phenmetrazine	The risk or severity of hypertension can be increased when Phenmetrazine is combined with Metamfetamine.
Phenobarbital	The serum concentration of Phenobarbital can be decreased when it is combined with Metamfetamine.
Phenoxybenzamine	The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Metamfetamine.
Phenoxypropazine	Phenoxypropazine may increase the hypertensive activities of Metamfetamine.
Phentermine	The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Metamfetamine.
Phentolamine	The therapeutic efficacy of Phentolamine can be decreased when used in combination with Metamfetamine.
Phenylbutazone	The risk or severity of hypertension can be increased when Phenylbutazone is combined with Metamfetamine.
Phenylbutyric acid	The metabolism of Metamfetamine can be decreased when combined with Phenylbutyric acid.
Phenylephrine	The metabolism of Phenylephrine can be decreased when combined with Metamfetamine.
Phenylpropanol	The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Metamfetamine.
Phenytoin	The therapeutic efficacy of Phenytoin can be decreased when used in combination with Metamfetamine.
Pholcodine	Metamfetamine may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Metamfetamine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Phylloquinone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.

Picosulfuric acid	Metamfetamine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pimozide	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Pimozide.
Pinacidil	Metamfetamine may decrease the antihypertensive activities of Pinacidil.
Pindolol	The therapeutic efficacy of Pindolol can be decreased when used in combination with Metamfetamine.
Pipecuronium	The risk or severity of Tachycardia can be increased when Pipecuronium is combined with Metamfetamine.
Piperacillin	Piperacillin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Piperazine	The metabolism of Metamfetamine can be decreased when combined with Piperazine.
Pipotiazine	Pipotiazine may decrease the stimulatory activities of Metamfetamine.
Piracetam	The therapeutic efficacy of Metamfetamine can be increased when used in combination with Piracetam.
Pirbuterol	The risk or severity of hypertension can be increased when Pirbuterol is combined with Metamfetamine.
Pirenzepine	The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Metamfetamine.
Piretanide	Piretanide may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Pirfenidone	The metabolism of Pirfenidone can be decreased when combined with Metamfetamine.
Piritramide	Metamfetamine may increase the analgesic activities of Piritramide.
Piroxicam	The risk or severity of hypertension can be increased when Piroxicam is combined with Metamfetamine.
Pitolisant	Metamfetamine may decrease the sedative activities of Pitolisant.
Pivhydrazine	Pivhydrazine may increase the hypertensive activities of Metamfetamine.
Pizotifen	Metamfetamine may decrease the sedative activities of Pizotifen.
Plazomicin	Metamfetamine may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Metamfetamine may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Polythiazide	Metamfetamine may decrease the antihypertensive activities of Polythiazide.
Pomalidomide	Metamfetamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Metamfetamine.
Potassium	Potassium may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Metamfetamine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate	Metamfetamine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Potassium cation may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Potassium chloride	Potassium chloride may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Potassium citrate	The excretion of Metamfetamine can be decreased when combined with Potassium citrate.
Potassium Iodide	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Potassium Iodide.
Potassium nitrate	Metamfetamine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium perchlorate	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Potassium perchlorate.
Potassium sulfate	Metamfetamine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Practolol	The therapeutic efficacy of Practolol can be decreased when used in combination with Metamfetamine.
Pralatrexate	Metamfetamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralidoxime	Pralidoxime may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Pramipexole	Pramipexole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Prasugrel	Metamfetamine may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Prazosin	The therapeutic efficacy of Prazosin can be decreased when used in combination with Metamfetamine.
Prednisone	Prednisone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Pregabalin	Pregabalin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Primaquine	The metabolism of Metamfetamine can be decreased when combined with Primaquine.
Primidone	The serum concentration of Primidone can be decreased when it is combined with Metamfetamine.
Probenecid	Probenecid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Procainamide	The metabolism of Procainamide can be decreased when combined with Metamfetamine.
Procaine	Procaine may increase the hypertensive activities of Metamfetamine.
Procaine benzyl	Metamfetamine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine	Procarbazine may increase the hypertensive activities of Metamfetamine.
Procaterol	The risk or severity of hypertension can be increased when Procaterol is combined with Metamfetamine.
Prochlorperazine	Prochlorperazine may decrease the stimulatory activities of Metamfetamine.
Procyclidine	The risk or severity of Tachycardia can be increased when Procyclidine is combined with Metamfetamine.
Profenamine	The therapeutic efficacy of Profenamine can be decreased when used in combination with Metamfetamine.
Progesterone	The metabolism of Metamfetamine can be decreased when combined with Progesterone.
Proguanil	The metabolism of Metamfetamine can be decreased when combined with Proguanil.
Promazine	Metamfetamine may decrease the sedative activities of Promazine.
Promethazine	Metamfetamine may decrease the sedative activities of Promethazine.
Propafenone	The therapeutic efficacy of Propafenone can be decreased when used in combination with Metamfetamine.
Propantheline	Propantheline may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Propiomazine	Metamfetamine may decrease the sedative activities of Propiomazine.
Propiverine	The therapeutic efficacy of Propiverine can be decreased when used in combination with Metamfetamine.
Propofol	The risk or severity of hypertension can be increased when Propofol is combined with Metamfetamine.
Propranolol	The therapeutic efficacy of Propranolol can be decreased when used in combination with Metamfetamine.
Propylthiouracil	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Propylthiouracil.
Protirelin	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Protirelin.
Protokylol	The therapeutic efficacy of Metamfetamine can be increased when used in combination with Protokylol.
Protriptyline	The therapeutic efficacy of Protriptyline can be increased when used in combination with Metamfetamine.
Prucalopride	Metamfetamine may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Pseudoephedrine	The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Metamfetamine.
Pyrantel	Metamfetamine may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Pyrazinamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Pyridoxine	Pyridoxine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Quetiapine	Metamfetamine may decrease the sedative activities of Quetiapine.
Quinapril	Metamfetamine may decrease the antihypertensive activities of Quinapril.
Quinethazone	Quinethazone may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	The therapeutic efficacy of Quinidine can be decreased when used in combination with Metamfetamine.
Quinine	The metabolism of Metamfetamine can be decreased when combined with Quinine.
Quinupramine	The therapeutic efficacy of Quinupramine can be increased when used in combination with Metamfetamine.
Rabeprazole	Rabeprazole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Racepinephrine	The therapeutic efficacy of Metamfetamine can be increased when used in combination with Racepinephrine.
Ramelteon	Ramelteon may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ramipril	Metamfetamine may decrease the antihypertensive activities of Ramipril.
Ranitidine	Metamfetamine may decrease the sedative activities of Ranitidine.
Ranolazine	The serum concentration of Metamfetamine can be increased when it is combined with Ranolazine.
Rapacuronium	The risk or severity of Tachycardia can be increased when Metamfetamine is combined with Rapacuronium.
Rasagiline	Rasagiline may increase the hypertensive activities of Metamfetamine.
Reboxetine	The metabolism of Metamfetamine can be decreased when combined with Reboxetine.
Remifentanil	Metamfetamine may increase the analgesic activities of Remifentanil.
Remoxipride	Remoxipride may decrease the stimulatory activities of Metamfetamine.
Rescinnamine	Metamfetamine may decrease the antihypertensive activities of Rescinnamine.
Reserpine	The serum concentration of Metamfetamine can be decreased when it is combined with Reserpine.
Resorcinol	Metamfetamine may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Revefenacin	The metabolism of Revefenacin can be decreased when combined with Metamfetamine.
Ribavirin	Ribavirin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Ribostamycin	Metamfetamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rilmenidine	Metamfetamine may decrease the antihypertensive activities of Rilmenidine.
Rilonacept	The metabolism of Metamfetamine can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Metamfetamine can be decreased when combined with Rilpivirine.
Rimonabant	The risk or severity of Tachycardia can be increased when Rimonabant is combined with Metamfetamine.
Riociguat	Metamfetamine may decrease the antihypertensive activities of Riociguat.
Risperidone	Metamfetamine may decrease the sedative activities of Risperidone.

Ritodrine	The risk or severity of hypertension can be increased when Ritodrine is combined with Metamfetamine.
Ritonavir	The serum concentration of Metamfetamine can be increased when it is combined with Ritonavir.
Rivaroxaban	Metamfetamine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rizatriptan	The metabolism of Rizatriptan can be decreased when combined with Metamfetamine.
Rocuronium	The risk or severity of Tachycardia can be increased when Rocuronium is combined with Metamfetamine.
Rofecoxib	The risk or severity of hypertension can be increased when Rofecoxib is combined with Metamfetamine.
Roflumilast	Metamfetamine may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Rolapitant	The metabolism of Metamfetamine can be decreased when combined with Rolapitant.
Ropeginterferon	The metabolism of Metamfetamine can be decreased when combined with Ropeginterferon alfa-2b.
Ropivacaine	Ropivacaine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Rosiglitazone	Rosiglitazone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Rotigotine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Rotigotine.
Rucaparib	The metabolism of Metamfetamine can be decreased when combined with Rucaparib.
Rupatadine	Metamfetamine may decrease the sedative activities of Rupatadine.
Ruxolitinib	Metamfetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sacubitril	Metamfetamine may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Safinamide	Safinamide may increase the hypertensive activities of Metamfetamine.
Safrazine	Safrazine may increase the hypertensive activities of Metamfetamine.
Salicylamide	The risk or severity of hypertension can be increased when Metamfetamine is combined with Salicylamide.
Salicylic acid	The risk or severity of hypertension can be increased when Salicylic acid is combined with Metamfetamine.
Salmeterol	The risk or severity of hypertension can be increased when Salmeterol is combined with Metamfetamine.
Salmon calcitonin	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Salmon calcitonin.
Salsalate	The risk or severity of hypertension can be increased when Salsalate is combined with Metamfetamine.
Samidorphan	Samidorphan may decrease the stimulatory activities of Metamfetamine.
Saquinavir	The metabolism of Metamfetamine can be decreased when combined with Saquinavir.
Saxagliptin	Metamfetamine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Scopolamine	The risk or severity of Tachycardia can be increased when Scopolamine is combined with Metamfetamine.
Secobarbital	Secobarbital may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Secukinumab	The metabolism of Metamfetamine can be increased when combined with Secukinumab.
Selegiline	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Selegiline.
Selenious acid	Metamfetamine may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Metamfetamine may decrease the excretion rate of Selenium which could result in a higher serum level.
Selexipag	Metamfetamine may decrease the antihypertensive activities of Selexipag.
Selpercatinib	The risk or severity of hypertension can be increased when Metamfetamine is combined with Selpercatinib.
Serdexmethyl	The risk or severity of hypertension can be increased when Metamfetamine is combined with Serdexmethylphenidate.
Sertindole	Sertindole may decrease the stimulatory activities of Metamfetamine.
Sertraline	The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Metamfetamine.
Sevoflurane	The risk or severity of hypertension can be increased when Sevoflurane is combined with Metamfetamine.
Sibutramine	Sibutramine may increase the tachycardic activities of Metamfetamine.
Sildenafil	The metabolism of Metamfetamine can be decreased when combined with Sildenafil.
Silodosin	The therapeutic efficacy of Silodosin can be decreased when used in combination with Metamfetamine.
Siltuximab	The metabolism of Metamfetamine can be increased when combined with Siltuximab.
Simvastatin	The metabolism of Metamfetamine can be decreased when combined with Simvastatin.
Siponimod	The risk or severity of hypertension can be increased when Metamfetamine is combined with Siponimod.
Sitagliptin	Sitagliptin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Sitaxentan	Metamfetamine may decrease the antihypertensive activities of Sitaxentan.
Sodium acetate	Metamfetamine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium ascorbate	The serum concentration of Metamfetamine can be decreased when it is combined with Sodium ascorbate.
Sodium aurot	Metamfetamine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium bic	The serum concentration of Metamfetamine can be increased when it is combined with Sodium bicarbonate.
Sodium citrate	The excretion of Metamfetamine can be decreased when combined with Sodium citrate.
Sodium fluoride	Metamfetamine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium phosph	The serum concentration of Metamfetamine can be decreased when it is combined with Sodium phosphate, dibasic.
Sodium phospha	The serum concentration of Metamfetamine can be decreased when it is combined with Sodium phosphate, monobasic.
Sodium sulfate	Metamfetamine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir	Metamfetamine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solifenacin	The risk or severity of hypertension can be increased when Metamfetamine is combined with Solifenacin.
Solriamfetol	The risk or severity of hypertension can be increased when Solriamfetol is combined with Metamfetamine.
Sorafenib	Sorafenib may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Sorbitol	Metamfetamine may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Sotalol	The therapeutic efficacy of Sotalol can be decreased when used in combination with Metamfetamine.
Sotatercept	Metamfetamine may decrease the antihypertensive activities of Sotatercept.
Sparteine	The metabolism of Metamfetamine can be decreased when combined with Sparteine.
Spirapril	Metamfetamine may decrease the antihypertensive activities of Spirapril.
Spironolactone	The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Spironolactone.
St. John’s Wort	The risk or severity of serotonin syndrome can be increased when St. John’s Wort is combined with Metamfetamine.
Stiripentol	The metabolism of Metamfetamine can be decreased when combined with Stiripentol.
Streptomycin	Metamfetamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Strontium chloride	Metamfetamine may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Sucralfate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Sufentanil	Metamfetamine may increase the analgesic activities of Sufentanil.
Sulbactam	Metamfetamine may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	Sulfadiazine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Sulfamethoxazole	Sulfamethoxazole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Sulfaphenazole	The metabolism of Metamfetamine can be decreased when combined with Sulfaphenazole.
Sulfasalazine	The risk or severity of hypertension can be increased when Sulfasalazine is combined with Metamfetamine.
Sulindac	The risk or severity of hypertension can be increased when Sulindac is combined with Metamfetamine.
Sulpiride	Sulpiride may decrease the stimulatory activities of Metamfetamine.
Sultopride	Sultopride may decrease the stimulatory activities of Metamfetamine.
Sumatriptan	The metabolism of Sumatriptan can be decreased when combined with Metamfetamine.
Estrogens, A	Metamfetamine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Conjugated Estrogen	Metamfetamine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tacrolimus	Tacrolimus may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tadalafil	Metamfetamine may decrease the antihypertensive activities of Tadalafil.
Tafenoquine	The metabolism of Tafenoquine can be decreased when combined with Metamfetamine.
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Metamfetamine.
Tamsulosin	The therapeutic efficacy of Tamsulosin can be decreased when used in combination with Metamfetamine.
Tapentadol	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Tapentadol.
Tasimelteon	Metamfetamine may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Technetium	Metamfetamine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium	Metamfetamine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium	Metamfetamine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Technetium	Metamfetamine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Tedizolid phosphate	Tedizolid phosphate may increase the hypertensive activities of Metamfetamine.
Teduglutide	Metamfetamine may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Tegafur	Metamfetamine may decrease the excretion rate of Tegafur which could result in a higher serum level.
Tegaserod	The metabolism of Metamfetamine can be decreased when combined with Tegaserod.
Telavancin	Metamfetamine may decrease the excretion rate of Telavancin which could result in a higher serum level.
Telmisartan	Metamfetamine may decrease the antihypertensive activities of Telmisartan.
Temazepam	Temazepam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.

Temozolomide	Temozolomide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Temsirolimus	The metabolism of Metamfetamine can be decreased when combined with Temsirolimus.
Tenofovir alafen	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metamfetamine.
Tenofovir diso	Tenofovir disoproxil may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tenoxicam	The risk or severity of hypertension can be increased when Tenoxicam is combined with Metamfetamine.
Terazosin	The therapeutic efficacy of Terazosin can be decreased when used in combination with Metamfetamine.
Terbinafine	The metabolism of Metamfetamine can be decreased when combined with Terbinafine.
Terbutaline	The risk or severity of hypertension can be increased when Terbutaline is combined with Metamfetamine.
Terfenadine	Metamfetamine may decrease the sedative activities of Terfenadine.
Teriparatide	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Teriparatide.
Testolactone	Testolactone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Testosterone	Testosterone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Testosterone	Metamfetamine may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone	Metamfetamine may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone	Testosterone propionate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Testosterone	Testosterone undecanoate may increase the hypertensive activities of Metamfetamine.
Tetrabenazine	The metabolism of Tetrabenazine can be decreased when combined with Metamfetamine.
Tetracycline	Tetracycline may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tetradecyl hydro	Metamfetamine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Tetryzoline	The risk or severity of hypertension can be increased when Metamfetamine is combined with Tetryzoline.
Theophylline	The metabolism of Theophylline can be decreased when combined with Metamfetamine.
Thiabendazole	Thiabendazole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Thiethylperazine	Thiethylperazine may decrease the stimulatory activities of Metamfetamine.
Thioproperazine	The therapeutic efficacy of Thioproperazine can be decreased when used in combination with Metamfetamine.
Thioridazine	The therapeutic efficacy of Thioridazine can be decreased when used in combination with Metamfetamine.
Thiothixene	Thiothixene may decrease the stimulatory activities of Metamfetamine.
Thonzylamine	Metamfetamine may decrease the sedative activities of Thonzylamine.
Thyroid, porcine	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Thyroid, porcine.
Thyrotropin alfa	The risk or severity of adverse effects can be increased when Metamfetamine is combined with Thyrotropin alfa.
Tiaprofenic acid	The risk or severity of hypertension can be increased when Metamfetamine is combined with Tiaprofenic acid.
Ticlopidine	The metabolism of Metamfetamine can be decreased when combined with Ticlopidine.
Tienilic acid	Metamfetamine may decrease the antihypertensive activities of Tienilic acid.
Tiludronic acid	Tiludronic acid may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Timolol	The therapeutic efficacy of Timolol can be decreased when used in combination with Metamfetamine.
Tinidazole	Tinidazole may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tiopronin	Metamfetamine may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiotropium	Tiotropium may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tipranavir	The metabolism of Metamfetamine can be decreased when combined with Tipranavir.
Tirofiban	Tirofiban may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tixocortol	Metamfetamine may decrease the excretion rate of Tixocortol which could result in a higher serum level.
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Metamfetamine.
Tobramycin	Metamfetamine may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab	The metabolism of Metamfetamine can be increased when combined with Tocilizumab.
Tocopherol	Metamfetamine may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tolazamide	Tolazamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tolazoline	The therapeutic efficacy of Tolazoline can be decreased when used in combination with Metamfetamine.
Tolbutamide	Tolbutamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tolcapone	Tolcapone may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tolfenamic acid	The risk or severity of hypertension can be increased when Metamfetamine is combined with Tolfenamic acid.
Tolmetin	The risk or severity of hypertension can be increased when Tolmetin is combined with Metamfetamine.
Tolterodine	Tolterodine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Tolvaptan	Tolvaptan may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate	Topiramate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Topotecan	Topotecan may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Torasemide	Metamfetamine may decrease the antihypertensive activities of Torasemide.
Tositumomab	Tositumomab may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Metamfetamine.
Tramadol	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Tramadol.
Trametinib	Metamfetamine may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trandolapril	Metamfetamine may decrease the antihypertensive activities of Trandolapril.
Tranylcypromine	Tranylcypromine may increase the hypertensive activities of Metamfetamine.
Trazodone	The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Metamfetamine.
Treprostinil	Metamfetamine may decrease the antihypertensive activities of Treprostinil.
Tretinoin	The risk or severity of elevated intracranial pressure can be increased when Metamfetamine is combined with Tretinoin.
Triamterene	Triamterene may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Triazolam	Triazolam may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Trichlormethiazide	Metamfetamine may decrease the antihypertensive activities of Trichlormethiazide.
Trichloroethylene	The risk or severity of hypertension can be increased when Metamfetamine is combined with Trichloroethylene.
Triclabendazole	The metabolism of Metamfetamine can be decreased when combined with Triclabendazole.
Tridihexethyl	The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Metamfetamine.
Triethylenetetramine	Metamfetamine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Trifluoperazine	The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Metamfetamine.
Triflupromazine	Triflupromazine may decrease the stimulatory activities of Metamfetamine.
Trifluridine	Trifluridine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Trihexyphenidyl	The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Metamfetamine.
Trimebutine	Metamfetamine may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Trimethaphan	Metamfetamine may decrease the antihypertensive activities of Trimethaphan.
Trimethoprim	Trimethoprim may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Trimetrexate	Trimetrexate may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Trimipramine	Metamfetamine may decrease the sedative activities of Trimipramine.
Tripelennamine	Metamfetamine may decrease the sedative activities of Tripelennamine.
Triprolidine	Metamfetamine may decrease the sedative activities of Triprolidine.
Tritoqualine	Metamfetamine may decrease the sedative activities of Tritoqualine.
Tropisetron	Metamfetamine may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Trospium	The metabolism of Metamfetamine can be decreased when combined with Trospium.
Tryptophan	The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Metamfetamine.
Umeclidinium	The metabolism of Umeclidinium can be decreased when combined with Metamfetamine.
Vaborbactam	Metamfetamine may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Valbenazine	Metamfetamine may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib	The risk or severity of hypertension can be increased when Valdecoxib is combined with Metamfetamine.
Valganciclovir	Metamfetamine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Valproate bismuth	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Valproate bismuth.
Valproic acid	The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Metamfetamine.
Valsartan	Metamfetamine may decrease the antihypertensive activities of Valsartan.
Vancomycin	Metamfetamine may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Varenicline	Varenicline may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Vemurafenib	The metabolism of Metamfetamine can be decreased when combined with Vemurafenib.
Venlafaxine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Venlafaxine.
Verapamil	The therapeutic efficacy of Verapamil can be decreased when used in combination with Metamfetamine.

Vernakalant	The metabolism of Vernakalant can be decreased when combined with Metamfetamine.
Vilanterol	The risk or severity of hypertension can be increased when Metamfetamine is combined with Vilanterol.
Vilazodone	The metabolism of Metamfetamine can be decreased when combined with Vilazodone.
Viloxazine	The metabolism of Metamfetamine can be decreased when combined with Viloxazine.
Vinblastine	The metabolism of Metamfetamine can be decreased when combined with Vinblastine.
Vinorelbine	The metabolism of Metamfetamine can be decreased when combined with Vinorelbine.
Vortioxetine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Vortioxetine.
Warfarin	Metamfetamine may decrease the excretion rate of Warfarin which could result in a higher serum level.
Xamoterol	The risk or severity of hypertension can be increased when Metamfetamine is combined with Xamoterol.
Xanomeline	The metabolism of Xanomeline can be decreased when combined with Metamfetamine.
Xylometazoline	The risk or severity of hypertension can be increased when Metamfetamine is combined with Xylometazoline.
Yohimbine	The therapeutic efficacy of Yohimbine can be decreased when used in combination with Metamfetamine.
Zaleplon	Zaleplon may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Zanamivir	Zanamivir may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Zimelidine	The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Zimelidine.
Zinc ascorbate	The serum concentration of Metamfetamine can be decreased when it is combined with Zinc ascorbate.
Ziprasidone	Metamfetamine may decrease the sedative activities of Ziprasidone.
Zofenopril	Metamfetamine may decrease the antihypertensive activities of Zofenopril.
Zolmitriptan	The metabolism of Zolmitriptan can be decreased when combined with Metamfetamine.
Zolpidem	The metabolism of Metamfetamine can be decreased when combined with Zolpidem.
Zomepirac	The risk or severity of hypertension can be increased when Metamfetamine is combined with Zomepirac.
Zonisamide	Zonisamide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Zotepine	Zotepine may decrease the stimulatory activities of Metamfetamine.
Zuclopenthixol	Metamfetamine may decrease the sedative activities of Zuclopenthixol.

Pregnancy and Lactation

Because there is no published experience with methamphetamine as a therapeutic agent during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. One expert recommends that amphetamines not be used therapeutically in nursing mothers.

Methamphetamine should not be used as a recreational drug by nursing mothers because it may impair their judgment and childcare abilities. Methamphetamine and its metabolite, amphetamine, are detectable in breastmilk and infant’s serum after abuse of methamphetamine by nursing mothers. However, these data are from random collections rather than controlled studies because of ethical considerations in administering recreational methamphetamine to nursing mothers. Other factors to consider are the possibility of positive urine tests in breastfed infants which might have legal implications, and the possibility of other harmful contaminants in street drugs. Breastfeeding is generally discouraged in mothers who are actively abusing amphetamines. In mothers who abuse methamphetamine while nursing, withholding breastfeeding for 48 to 100 hours after the maternal use been recommended, although in many mothers methamphetamine is undetectable in breastmilk after an average of 72 hours from the last use. It has been suggested that breastfeeding can be reinstated 24 hours after a negative maternal urine screen for amphetamines.

Effects in Breastfed Infants

A 2-month-old infant whose mother used illicit street methamphetamine recreationally by nasal inhalation was found dead 8 hours after a small amount of breastfeeding and ingestion of 120 to 180 mL of formula. The infant’s serum methamphetamine concentration on autopsy was 39 mcg/L. Although the infant’s mother was convicted of child endangerment for the use of methamphetamine during breastfeeding, the role that methamphetamine played in the infant’s death has been questioned because of the low infant serum methamphetamine concentration and the mother’s alleged minimal breastfeeding.

South Australian government pathologists reported the death of a breastfed infant who was co-sleeping with its mother. Methamphetamine was found in a “significant” concentration in the infant on autopsy and the drug in breastmilk was thought to be potentially contributory to the death. These authors also reported that in prior deaths of infants under 12 months of age, detectable methamphetamine and its metabolite, amphetamine, may have been partially obtained via breastmilk. Pathologists from the New Zealand government confirmed similar findings in their country.

Effects on Lactation and Breastmilk

A single oral dose of 0.2 mg/kg to a maximum of 17.5 mg of d-methamphetamine was given to 6 subjects (4 male and 2 female). Serum prolactin concentrations were unchanged over a period of 300 minutes after the dose.

In 2 papers by the same authors, 20 women with normal physiologic hyperprolactinemia were studied on days 2 or 3 postpartum. Eight received dextroamphetamine 7.5 mg intravenously, 6 received 15 mg intravenously and 6 who served as controls received intravenous saline. The 7.5 mg dose reduced serum prolactin by 25 to 32% compared to control, but the difference was not statistically significant. The 15 mg dose significantly decreased serum prolactin by 30 to 37% at times after the infusion. No assessment of milk production was presented. The authors also quoted data from another study showing that a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40% in postpartum women.

FAQ

◈ What is methamphetamine?

Methamphetamine is also known as metamfetamine, methylamphetamine, and desoxyephedrine. Other names for methamphetamine include “meth,” “crystal meth,” “crank,” “speed” or “ice.” Methamphetamine has been smoked, snorted, swallowed, injected, inhaled, taken rectally, or dissolved under the tongue.Methamphetamine has been used illegally without medical supervision. It has also been prescribed by a healthcare provider for attention deficit hyperactivity disorder (ADHD). This sheet will focus on the use of methamphetamine without medical supervision.

◈ I take methamphetamine. Can it make it harder for me to get pregnant?

Methamphetamine has not been studied to see if using it could make it harder to get pregnant.

◈ I just found out that I am pregnant, should I stop taking methamphetamine?

If you are using methamphetamine without medical supervision (sometimes called recreational use), treatment is available to help you stop. Talk to your healthcare provider as soon as possible so that you can start treatment. If you do not have a healthcare provider, call the national number for drug treatment referral at 800-662-4357. When you call, let them know that you are pregnant so that you can get connected to the best facility to meet your needs.

◈ Does taking methamphetamine increase the chance of miscarriage?

Miscarriage is common and can occur in any pregnancy for many different reasons. Based on the studies reviewed, methamphetamine use might increase the chance for miscarriage.

◈ Does taking methamphetamine increase the chance of birth defects?

Every pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk. Based on the studies reviewed, it is not known if methamphetamine increases the chance for birth defects above the background risk. Information on whether methamphetamine increases the chance of birth defects is mixed. This makes it hard to know the actual risks for each person who uses methamphetamine.

◈ What can I do to find out if the baby has a birth defect or other problems?

It is important to talk with your healthcare provider about any exposures you have had during your pregnancy. They can help you find treatment or support and can go over any screening options that are available. A detailed ultrasound can screen for some birth defects. There is no test in pregnancy that can look for learning problems. Once your baby is born, you should also tell your child’s healthcare provider so your baby can get the care that is best for them.

◈ Does taking methamphetamine in pregnancy increase the chance of other pregnancy-related problems?

Methamphetamine use has been linked to a higher chance for preterm delivery (delivery before 37 weeks of pregnancy), poor growth (babies born too small and/or with a small head size), and low birth weight (weighing less than 5 pounds, 8 ounces [2500 grams] at birth). Some studies have suggested that methamphetamine use in pregnancy can increase the chance for high blood pressure, placental abruption (the placenta pulls away from the uterus) and for fetal death or infant death. Some studies also show an association between methamphetamine misuse and a higher chance of postpartum mood disorders. Pregnancy complications are more likely to happen when methamphetamine is used throughout the whole pregnancy or when taken at high doses.

◈ Will my baby have withdrawal if I continue to take methamphetamine?

When people who are pregnant use methamphetamines near the end of their pregnancy, babies could show signs of withdrawal after they are born. Symptoms can include trouble eating, sleeping too little or too much, having floppy (poor) muscle control or tight muscles, being jittery, and / or having a hard time breathing. Withdrawal symptoms usually go away within a few weeks but can last for a few months. The baby might need to be admitted to the special care nursery (NICU). It is important that your healthcare providers know you are taking methamphetamine so that if symptoms occur your baby can get the care that is best for them.

◈ Does taking methamphetamine in pregnancy affect future behavior or learning for the child?

Studies have suggested that children who were exposed to methamphetamine during pregnancy could have a higher chance for changes in their brain development, as well as learning and behavior problems later in life.

◈ Breastfeeding while taking methamphetamine:

Methamphetamine can pass into breast milk. Methamphetamine should not be used without medical supervision while breastfeeding. If methamphetamine is used, it has been suggested to express and discard breastmilk for 48-100 hours. Be sure to talk to your healthcare provider about all of your breastfeeding questions.

◈ If a male takes methamphetamine, could it affect fertility (ability to get partner pregnant) or increase the chance of birth defects?

Methamphetamine misuse might affect the sperm, making it harder to get someone pregnant. Studies have not been done to see if methamphetamine could increase the chance of birth defects above the background risk. In general, exposures that fathers or sperm donors have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/005378s034lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/005378s038lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/005378s026lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021121s035lbl.pdf
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a5d7233-4453-42a5-8144-a4276db39660

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fd6b3a8-b17b-4b98-ad03-a8af7b6f3368
https://pubchem.ncbi.nlm.nih.gov/compound/Methamphetamine
https://medlineplus.gov/methamphetamine.html
https://www.drugs.com/methamphetamine.html
DrugBank

(http://creativecommons.org/licenses/by-nc/4.0/legalcode)

https://www.drugbank.ca/legal/terms_of_use

https://www.drugbank.ca/drugs/DB01577
DTP/NCI
https://www.cancer.gov/policies/copyright-reuse

METHAMPHETAMINE

https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=25115
EPA DSSTox

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

Methamphetamine

https://comptox.epa.gov/dashboard/DTXSID8037128

https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)
https://echa.europa.eu/web/guest/legal-notice

Methamphetamine

https://chem.echa.europa.eu/100.007.882

Methamphetamine (EC: 208-668-7)

https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/70387
FDA Global Substance Registration System (GSRS)
https://www.fda.gov/about-fda/about-website/website-policies#linking

METHAMPHETAMINE

https://gsrs.ncats.nih.gov/ginas/app/beta/substances/44RAL3456C
Hazardous Substances Data Bank (HSDB)

LICENSE

https://www.nlm.nih.gov/web_policies.html

d-METHAMPHETAMINE

https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3359
Human Metabolome Database (HMDB)
http://www.hmdb.ca/citing

Methamphetamine

http://www.hmdb.ca/metabolites/HMDB0015517

HMDB0015517_msms_2227341

https://hmdb.ca/metabolites/HMDB0015517#spectra
CCSbase

CCSbase Classification

https://ccsbase.net/
ChEBI

Methamphetamine

https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6809

ChEBI Ontology

http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
FDA Pharm Classes
https://www.fda.gov/about-fda/about-website/website-policies#linking

METHAMPHETAMINE

https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm

FDA Pharmacological Classification

https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class
LOTUS – the natural products occurrence database
https://lotus.nprod.net/

Methamphetamine

https://www.wikidata.org/wiki/Q191924

LOTUS Tree

https://lotus.naturalproducts.net/
NCI Thesaurus (NCIt)
https://www.cancer.gov/policies/copyright-reuse

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61840

NCI Thesaurus

https://ncit.nci.nih.gov
Open Targets
https://platform-docs.opentargets.org/licence

METHAMPHETAMINE

https://platform.opentargets.org/drug/CHEMBL1201201
Toxin and Toxin Target Database (T3DB)
http://www.t3db.ca/downloads

Methamphetamine

http://www.t3db.ca/toxins/T3D3052
ChEMBL

(http://www.ebi.ac.uk/Information/termsofuse.html). http://creativecommons.org/licenses/by-sa/3.0/).

http://www.ebi.ac.uk/Information/termsofuse.html

https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201201

ChEMBL Protein Target Tree

https://www.ebi.ac.uk/chembl/g/#browse/targets
ClinicalTrials.gov
https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use

https://clinicaltrials.gov/
Comparative Toxicogenomics Database (CTD)
http://ctdbase.org/about/legal.jsp

Methamphetamine

https://ctdbase.org/detail.go?type=chem&acc=D008694
Drug Gene Interaction database (DGIdb)
http://www.dgidb.org/downloads

METHAMPHETAMINE

https://www.dgidb.org/drugs/rxcui:6816
Therapeutic Target Database (TTD)

Methamphetamine

https://idrblab.net/ttd/data/drug/details/D0P6UB
Drug Enforcement Administration (DEA)
https://www.justice.gov/legalpolicies

Methamphetamine

https://www.deadiversion.usdoj.gov/drug_chem_info/
Drug Induced Liver Injury Rank (DILIrank) Dataset
https://www.fda.gov/about-fda/about-website/website-policies#linking

methamphetamine

https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
StatPearls

https://www.ncbi.nlm.nih.gov/books/n/statpearls/article-25068/
NORMAN Suspect List Exchange
https://creativecommons.org/licenses/by/4.0/

https://www.norman-network.com/nds/SLE/
Drugs and Lactation Database (LactMed)

LICENSE

https://www.nlm.nih.gov/copyright.html

Methamphetamine

https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM715/
Mother To Baby Fact Sheets
https://www.ncbi.nlm.nih.gov/books/about/copyright/

methamphetamine

https://www.ncbi.nlm.nih.gov/books/n/mtb/methamphetamine-en/
EPA Chemical and Products Database (CPDat)

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

https://comptox.epa.gov/dashboard/DTXSID8037128#exposure

EPA CPDat Classification

https://www.epa.gov/chemical-research/chemical-and-products-database-cpdat
Japan Chemical Substance Dictionary (Nikkaji)
http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J6.362B
KEGG
https://www.kegg.jp/kegg/legal.html

https://www.kegg.jp/entry/C07164

https://www.kegg.jp/entry/D08187

Anatomical Therapeutic Chemical (ATC) classification

http://www.genome.jp/kegg-bin/get_htext?br08303.keg

Target-based classification of drugs

http://www.genome.jp/kegg-bin/get_htext?br08310.keg

Drug Groups

http://www.genome.jp/kegg-bin/get_htext?br08330.keg
MassBank Europe

LICENSE

https://github.com/MassBank/MassBank-web/blob/main/MassBank-Project/LICENSE.txt

Methamphetamine

https://massbank.eu/MassBank/Result.jsp?inchikey=MYWUZJCMWCOHBA-VIFPVBQESA-N
MassBank of North America (MoNA)

LICENSE

The content of the MoNA database is licensed under CC BY 4.0.

https://mona.fiehnlab.ucdavis.edu/documentation/license

Methamphetamine

https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists(compound.metaData.name:%27InChIKey%27%20and%20compound.metaData.value:%27MYWUZJCMWCOHBA-VIFPVBQESA-N%27)
Metabolomics Workbench

Methamphetamine

https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=43571
NIPH Clinical Trials Search of Japan
https://rctportal.niph.go.jp/en/
NIST Mass Spectrometry Data Center

LICENSE

Data covered by the Standard Reference Data Act of 1968 as amended.

https://www.nist.gov/srd/public-law

Methamphetamine

http://www.nist.gov/srd/nist1a.cfm
NLM RxNorm Terminology
https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html

methamphetamine

https://rxnav.nlm.nih.gov/id/rxnorm/6816
PharmGKB

(https://creativecommons.org/licenses/by-sa/4.0/).

https://www.pharmgkb.org/page/policies

methamphetamine

https://www.pharmgkb.org/chemical/PA450403
Pharos
https://pharos.nih.gov/about

methamphetamine

https://pharos.nih.gov/ligands/MYD86PBPJS3F
Protein Data Bank in Europe (PDBe)
http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/B40
RCSB Protein Data Bank (RCSB PDB)
https://www.rcsb.org/pages/policies

https://www.rcsb.org/
SpectraBase

D-Methamphetamine

https://spectrabase.com/spectrum/706bQwYiZbF

Methamphetamine

https://spectrabase.com/spectrum/JoVnfiRvajz
Springer Nature
https://pubchem.ncbi.nlm.nih.gov/substance/341239136

https://pubchem.ncbi.nlm.nih.gov/substance/341142009
SpringerMaterials

N,Î±-Dimethyl-phenethyl amine

https://materials.springer.com/substanceprofile/docs/smsid_algfmsgcstksyytx
Thieme Chemistry
https://creativecommons.org/licenses/by-nc-nd/4.0/

https://pubchem.ncbi.nlm.nih.gov/substance/376882817

https://pubchem.ncbi.nlm.nih.gov/substance/376358663
WHO Anatomical Therapeutic Chemical (ATC) Classification
https://www.whocc.no/copyright_disclaimer/

Metamfetamine

https://www.whocc.no/atc_ddd_index/?code=N06BA03

EPA CPDat Classification

https://www.whocc.no/atc_ddd_index/
Wikidata

LICENSE

CCZero

https://creativecommons.org/publicdomain/zero/1.0/

D-methamphetamine

https://www.wikidata.org/wiki/Q191924
Wikipedia

Methamphetamine

https://en.wikipedia.org/wiki/Methamphetamine
Wiley
https://pubchem.ncbi.nlm.nih.gov/substance/386269680
Medical Subject Headings (MeSH)
https://www.nlm.nih.gov/copyright.html

Methamphetamine

https://www.ncbi.nlm.nih.gov/mesh/68008694

MeSH Tree

http://www.nlm.nih.gov/mesh/meshhome.html

Adrenergic Uptake Inhibitors

https://www.ncbi.nlm.nih.gov/mesh/68018759

Dopamine Agents

https://www.ncbi.nlm.nih.gov/mesh/68015259

Adrenergic Agents

https://www.ncbi.nlm.nih.gov/mesh/68018663

Dopamine Uptake Inhibitors

https://www.ncbi.nlm.nih.gov/mesh/68018765

Sympathomimetics

https://www.ncbi.nlm.nih.gov/mesh/68013566

Central Nervous System Stimulants

https://www.ncbi.nlm.nih.gov/mesh/68000697
PubChem
https://pubchem.ncbi.nlm.nih.gov
GHS Classification (UNECE)

GHS Classification

http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
EPA Substance Registry Services

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

EPA SRS List Classification

https://maldi.nist.gov
MolGenie
https://creativecommons.org/licenses/by/4.0/

MolGenie Organic Chemistry Ontology

https://github.com/MolGenie/ontology/
PATENTSCOPE (WIPO)

SID 403389668

https://pubchem.ncbi.nlm.nih.gov/substance/403389668
NCBI
https://www.ncbi.nlm.nih.gov/projects/linkout

References

SaveSavedRemoved 0

Methamphetamine – Uses, Dosage, Side Effects, Interactions

Mechanism of Action

Drug Indications

Contraindications

Dosage

Pediatric Dose for Attention Deficit Disorder

Administration advice:

General:

Side Effects

The Most Common

More Common

Rare

Drug Interactions

Pregnancy and Lactation

Pregnancy and Lactation

Effects in Breastfed Infants

Effects on Lactation and Breastmilk

FAQ

◈ What is methamphetamine?

◈ I take methamphetamine. Can it make it harder for me to get pregnant?

◈ I just found out that I am pregnant, should I stop taking methamphetamine?

◈ Does taking methamphetamine increase the chance of miscarriage?

◈ Does taking methamphetamine increase the chance of birth defects?

◈ What can I do to find out if the baby has a birth defect or other problems?

◈ Does taking methamphetamine in pregnancy increase the chance of other pregnancy-related problems?

◈ Will my baby have withdrawal if I continue to take methamphetamine?

◈ Does taking methamphetamine in pregnancy affect future behavior or learning for the child?

◈ Breastfeeding while taking methamphetamine:

◈ If a male takes methamphetamine, could it affect fertility (ability to get partner pregnant) or increase the chance of birth defects?

T2–T3 Intervertebral Disc Sequestration

Methamphetamine Hydrochloride - Uses, Dosage, Side Effects, Interaction

Vasodilator Drugs

Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

Vitamin D3 – Uses, Dosage, Side Effects, Interactions

Imidazole – Uses, Dosage, Side Effects, Interactions

To Get Daily Health Newsletter